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Abstract
Loss of heterozygosity (LOH) is detectable in many forms of cancer including
leukaemia. It contributes to tumorigenesis through the loss of one of the two alleles of
one tumor suppressor gene at a given locus, caused by deletion or uniparental
disomy (UPD). UPD can only be the result of homologous recombination. Little is
known about the mechanisms of UPD and what connection this aberration has with
the outcome of this disease.
In this study, 146 patients with primary AML were analysed using a novel technique
based on single nucleotide polymorphisms (SNPs). Leukaemic cells and healthy T-
cells from each patient were obtained using FACS-Vantage cell sorting. In cases with
very few sorted cells whole genome preamplification was done. Genome-wide SNP
analysis was carried out according to the standard GeneChip Mapping Assay
protocol (Affymetrix, USA) using the Human Mapping 10K Arrays. Moreover, the
impact of the FLT3-ITD mutation on the homologous recombination using pmHPRT-
DRGFP /pCbASce vectors system and yHA2x assay was investigated.
Of 146 patients with normal karyotype LOH was found in 30 cases. The potential
LOH regions, were confirmed by microsatellite analysis of short tandem repeat (STR)
markers. In 21 of these cases STR-analysis of T-cells, representing the
corresponding tumor-free material, confirmed the regions of partial UPD. This
aberration affected different chromosomes, but most commonly chr. 2, 6, 11, 21, 13,
and 7, and covered between 11.5 and 88 Mb. Interestingly, in 6 LOH cases, long
stretches of homozygosity present at the same positions as in the healthy cells and in
the blasts were found. The impact of this phenomenon is unknown. Additionally,
chromosome losses were detected in 3 patients classified with normal karyotype
according to current methods. These 9 cases were not included in the UPD positive
group.
No differences were observed regarding any clinical factors including age, WBC-
counts and sex. The FAB M1 subtype was observed in 47.6% of the UPD positive
patients, compared to only 19.2% of the UPD negative patients (P=0.04, n=146). In
addition, no correlation between FLT3-ITD, MLL-PTD and NPM1 mutations in the
UPD patients was found, but the data indicate that patients with UPD have a higher
rate of treatment failure.
Moreover, in this study the relationship between UPD and gene aberrations was able
to be confirmed. In some cases, UPD found on chromosomes 21, 19 and 11 was
correlated with mutations in the RUNX1, CEBPA and WT genes, respectively.
Furthermore, AML cases with and without UPD showed different but specific gene
expression profiles, revealing different expression levels for genes involved in double
strand break repairs.
Furthermore, it was found that different mutations could be responsible for the
increase in efficiency of HR, such as FLT3-ITD or BCR-ABL. Moreover, cells with a
FLT3-ITD  mutation (without wt expression) rapidly increased the HR efficiency
compared with heterozygous (FLT3-ITD/wt) cells. Preliminary results showed that the
high repair efficiency was mainly dependent on the translocation of RAD51.
In conclusion, SNP array technology allow the identification and mapping of LOH in
AML patients with normal karyotype. The obtained data also point out the necessity
of analysing tumour-free material to confirm the somatic origin of the alteration.
Furthermore, the available results indicate that compared to patients without UPD,
patients with UPD have a higher relapse rate, which might be used as a prognostic
marker in the future. Also, it could be hypothesized that downregulation of RAD51
(for example by FLT3 inhibition) might be beneficial DNA damage occurs through the
genotoxic agent by reducing the relapse risk of AML.
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1. Introduction
In 1845 the British pathologist John Hughes Bennett and the German pathologist
Rudolf Virchow described leukaemia as a lethal disease characterized by
enlargement of the spleen, and an excess of cells in the blood. Both claimed to have
been the first who described leukaemia, but actually one year earlier the French
physician Alfred Donné had published the first description of this disease in his book
“Complimentary course on microscopy for medical studies”. He was the first who
believed that the excess of white blood cells is due to an arrested maturation of blood
and it should be the result of an arrested development of intermediate cells.
Today we know that Donné was right. Leukaemia (Greek for “white blood”) is a type
of cancer that is characterized by uncontrolled immaturation of blood cells in the
bone marrow. The bone marrow is normally responsible for haematopoiesis –
formation of new blood cells. This (haematopoiesis) is a highly organized and
balanced process of cell proliferation, differentiation, maturation and survival. In
cases of leukaemia, malignant cells replace the population of healthy blood cells.
This results in anaemia, internal bleeding and increased susceptibility to infection.
Ultimately, leukaemic cells enter the peripheral blood circulation and infiltrate other
organs such as spleen, liver, and kidneys. Untreated, leukaemia is a lethal disease.
Leukaemia is a collective name for over a dozen of different blood malignancies.
Recent progress in the molecular biologic methods has allowed the characterisation
of different leukaemia subtypes. Depending on the lineage of the cell in which the
leukaemia originates, this disease can be divided into lymphoid (or lymphocytic) and
non-lymphoid (or myeloid) leukaemia. Both lymphoid and myeloid leukaemias can be
further classified into acute and chronic. Acute leukaemias progress rapidly involving
highly immature haematopoietic progenitors that are only limitedly differentiated. In
contrast, chronic leukaemias involve well-differentiated (but immunologically
incompetent) cells and usually develop more slowly.
In this project I focus on adult patients with acute myeloid leukaemia (AML). It has
been found that this disease is genetically very heterogeneous and is associated with
diverse cytogenetic abnormalities such as chromosomal deletions, translocations and
duplications. The diagnosis of the karyotype is one of the most important factors to
determine patient outcome. The development of new methods of diagnosis and the
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classification of different genetic aberrations present in leukaemia is very important
for the treatment of this disease
1.2 Haematopoiesis
Haematopoiesis is the development of blood cells. Postnatally, haematopoiesis
occurs mainly in the bone marrow. All mature blood cells are generated from a
relatively small number of pluripotent haematopoietic stem cells (Till and McCulloch,
1961). They generate the various haematopoietic lineages through a successive
series of intermediate progenitors (Dzierzak et al., 2005; Lemischka et al., 2001;
Weissman et al., 2000). The initial differentiation of pluripotent stem cells will follow
one of two major pathways, lymphoid or myeloid. Stem cells then become progenitor
cells for each type of mature blood cell. These cells have lost the capacity for self-
renewal and are committed to a given cell lineage: T- and B- progenitors (Kondo et
al., 1997) and progenitor cells for erythrocytes, neutrophils, eosinophils, basophils,
monocytes, mast cells and platelets (Akashi et al., 2000) (Fig.1.1)
Haematopoiesis is a continuous process throughout adulthood. Production of mature
blood cells equals their loss. Cell division and differentiation during haematopoiesis
are balanced by apoptosis – there must be maintenance of a stable state.
Haematopoietic cells grow and mature on a meshwork of non-haematopoietic
stromal cells. The accumulation, maturation, differentiation and survival of the
haematopoietic cells are caused by certain growth factors – small molecules with a
biologically active concentration lower than 10-12 M, that are mainly provided by the
stromal cells.
The first differentiation step to myeloid or to lymphoid progenitor cells is caused by
the Stem Cell Factor (SCF). Under the impact of other growth factors like Interleukin-
3 (IL-3), Erythropoietin (EPO), Granulocyte-macrophage colony stimulating factor
(GM-CSF), Granulocyte colony stimulating factor (G-CSF) and Thrombopoietin
(TPO), erythrocytes, macrophages,  granulocytes and thrombocytes maturate for
about 10 days. When this process is completed, the blood cells migrate to the
bloodstream and to different body tissues.
The differentiation of the lymphoid stem cells into B- and T- lymphocytes is caused
by different interleukins. (Reya et al., 2001; Speck and Gilliland, 2002).
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Fig.1.1 Normal haematopoiesis.
1.3 Acute myeloid leukaemia
Acute myeloid leukaemia (AML) is the most common acute leukaemia affecting
adults, with an age-dependent mortality of 2.7 to nearly 18 per 100,000 people
(Deschler and Lübbert, 2006). The median age of patients with AML is 65 to 70
years. The risk factors for acquiring AML include exposure to ionising radiation,
benzene, and cytotoxic chemotherapy.
Acute myeloid leukaemia represents a heterogeneous group of early stem cell
disorders. They are characterized by an uncontrolled expansion of malignant cells
(“blasts”) which are blocked at certain stages of myeloid differentiation. (Ailles et al.,
1997; Haase et al., 1995; Mehrotra et al., 1995). In absence of treatment this leads to
fatal infection, bleeding, or organ infiltration typically within one year of diagnosis.
The outcome for patients with AML depends greatly on the age of the patient and
leukaemic cell karyotype (Grimwade et al., 1998). For this reason the diagnoses and
the classification of different abnormalities is very important for the treatment.
Introduction 4
1.3.1 Classification
There are two systems for routine classification of AML. The first is the French-
American-British (FAB) system, based on morphologic histochemic and immunologic
analysis (Table 1.1) (Bennett et al., 1976). The second is the World Health
Organisation (WHO) system (Harris et al., 1999). A basic principle of the WHO
system is that the classification of haematopoietic and lymphoid neoplasm should
utilize not only morphologic findings but also all available information, including
genetic, immunophenotypic, biologic, and clinical features to define specific disease
properties (Table 1.2).
Table 1.1 FAB classification (Bennett et al., 1976).
French-American-British (FAB) Classification of acute myeloid leukaemia
M0     Undifferentiated AML
M1     Myeloblastic, without maturation
M2     Myeloblastic, with maturation and with or without t(8;21) (Tenen,
           2003).
M3     Promyelocytic, or acute promyelocytic leukaemia (APL) with
           t(15;17)(q22;q12)
M4     Myelomonocytic
M4eo   Myelomonocytic together with bone marrow eosinophilia
M5a    Monoblastic leukaemia
M5b    Monocytic leukaemia
M6      Erythrocytic or erythroleukaemia
M7     Megakatyoblastic
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Table 1.2 WHO classification (2008).
World Health Organisation (WHO) Classification of AML
Acute myeloid leukaemia with recurrent genetic abnormalities
AML with t(8;21)(q22;q22);(RUNX1-RUNX1T1)
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);(CBFB-MYH11)
APL with t(15;17)(q22;q12);(PML-RARA)
AML with t(9;11)(p22;q23);(MLLT3-MLL)
AML with t(6;9)(p23;q34);(DEK-NUP214)
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2);(RPN1-EVI1)
AML (megakaryoblastic) with t(1;22)(p13;q13);(RBM15-MKL1)
Provisional entity: AML with mutated NPM1
Provisional entity: AML with mutated CEBPA
AML with myelodysplasia-related changes
Prior history of myelodysplastic syndrome (MDS)
MDS-related cytogenetic abnormality
Multilineage dysplasia
Therapy-related myeloid neoplasms
Acute myeloid leukemia, not otherwise specified
AML with minimal differentiation
AML without maturation
AML with maturation
Acute myelomonocytic leukemia
Acute monoblastic/monocytic leukemia
Acute erythroid leukemia
Acute megakaryoblastic leukemia
Acute basophilic leukemia
Acute panmyelosis with myelofibrosis
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1.3.2 Genetic variations
Acute myeloid leukaemia is a clinically and genetically very heterogeneous disease
(Estay and Döhner, 2006). Numerous cytogenetic studies have described more than
200 different structural and numerical aberrations (Mrózek et al., 2001). Little is
known about the mechanisms leading to the development of chromosome
aberrations in cancer. Therefore, the cytogenetic diagnosis is a very important factor
for the achievement of complete remission (CR), a low relapse risk and survival
(Bloomfield et al., 1984; Grimwade et al., 1998, 2001; Slovak et al., 2000; Mrózek et
al., 2001, 2004; Byrd et al., 2002; Schoch et al., 2004; Farag et al., 2006).
Clonal chromosome aberrations are observed by current techniques in approximately
55% of patients with de novo acute myeloid leukaemia (AML). There are two general
types: the balanced and the unbalanced aberrations. In the remaining group of about
45% of the patients, a normal karyotype is detected.  According to cytogenetics and
dependent on the prognosis, AML patients are currently classified into three groups –
with favourable, intermediate and adverse prognosis (Grimwade et al., 1998; Schoch
et al., Oncology Reports 2002; Bloomfield et al., 1997; Mrozek et al., 1997).
1.3.2.1 Balanced chromosome abnormality
The primary balanced translocations occur in 20-25% of AML cases. These
abnormalities are characterized by primary reciprocal translocations or inversions,
with rearrangements but without visible gains or loses of chromosomal material. For
each of the balanced aberrations the break points are highly conserved from case to
case. These kinds of aberrations tend to be found in younger patients. Biologically,
several AMLs with balanced aberrations involve the deregulation of transcription
factors resulting in an impairment of cell differentiation and proliferation (Melnick et
al., 1999; Goger et al., 1999).
The most common balanced abnormalities in this group predict a favourable
prognosis are AML1-ETO t(8;21), occurring in 12-15% of the AML cases; CBFB-
MYH11 - inv(16) (p13;q22) that accounts for 8-10% of the cases of AML and PML-
RARA t(15;17) (Grimwade et al., 1998; Moorman et al., 2001). 11q23 translocations
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are also balanced aberrations but are associated with an unfavourable prognosis
(Schoch et al., 2003).
1.3.2.2 Unbalanced aberrations
35-40% of the AML cases have an unbalanced (complex) karyotype characterised by
visible gains or losses of rather larger regions of the genomes. One complex
karyotype is defined by detection of >3 abnormalities in one clone (excluding those
with recurrent balanced rearrangements) (Grimwade et al., 1998; Schoch et al.,
2002; Schoch et al., 2001; Swansbury et al., 1994). The chromosomal brake points
often show major variations from case to case. Furthermore these aberrations are
mostly characterized by a loss of genetic material resulting in an alteration of cell
cycle control and DNA repair. AMLs with non-balanced aberrations have a poor
prognosis with only 10-15 % long-term survivors.
Two of the most common unbalanced cytogenetic changes in therapy- and
chemically-related leukaemia are the loss and the deletion of the long (q) arm of
chromosomes 5 and 7 (Pedersen-Bjergaard et al., 1995). These specific
chromosome aberrations are also common among leukaemia patients with previous
exposure to chemical solvents, including chronic exposure to benzene, insecticides,
petroleum, etc. (Mitelman et al., 1981; Crane et al., 1996)
1.3.2.3 Normal karyotype
At diagnosis, about half (45%) of all AML patients have a normal karyotype, which
puts them at an intermediate risk of recurrence (Grimwade et al., 1998, 2001; Slovak
et al., 2000; Byrd et al., 2002). Only about 30% of karyotypically normal patients are
long term survivors (Farag et al., 2005). Thus, the identification of other molecular
markers should help improve the precision of prognostic stratification of the patients
in this group. By the use of molecular genetic techniques, such as reverse
transcription polymerase chain reaction (RT-PCR), fluorescence in situ hybridization
(FISH), direct sequencing and spectral karyotyping (SKY), some molecular
alternations with important prognostic impact were identified (Mrózek et al., 2007).
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One of the frequently detected abnormalities in AML patients with normal karyotype
is the internal tandem duplication (ITD) in the fms-like tyrosine kinase-3 gene (FLT3),
a haematopoietic growth factor receptor (Thiede et al., 2002; Nakao et al., 1996;
Kottaridis et al., 2001; Whitman et al., 2001; Fröhling et al., 2002; Kainz et al., 2002;
Schnittger et al., 2002; Beran et al., 2004). FLT3-ITD mutation is detected in 25% to
30% of the cases and is associated with poor treatment outcome. A second type of
mutation in the tyrosine kinase (TKD) domain of the FLT3 receptor is present in
approximately 5% to 7% of AML patients. The impact of FLT3-ITD mutation on other
mutations and on some cell mechanisms like DNA repair mechanism is an important
topic in this project. Therefore the formation and the function of FLT3 are described
in more detail below. Another molecular abnormality also associated with worse
prognosis is the presence of a partial tandem duplication of the mixed lineage
leukaemia gene (MLL-PTD) in approximately 8% of the cases (Schichman et al.,
1994; Caligiuri et al., 1998; Schnittger et al., 2000; Döhner et al., 2002; Shiah et al.,
2002; Munoz et al., 2003). Furthermore, some mutations were found in one of the
most important haematopoietic transcription factors - AML1/RUNX1. These
aberrations are common in adult haematologic malignancies, especially acute
myeloid leukaemia (AML)-M0 or leukaemia with acquired trisomy 21, and familial
platelet disorder with a predisposition toward AML. However, the prognostic
implication of RUNX1 mutations is limited.
Associated with a good clinical outcome are mutations in either the gene coding for
the transcription factor CEBPA (approximately 7% of the cases) (Pabst et al., 2001;
Preudhomme et al., 2002; Fröhling et al., 2004) or the most common somatic gene
mutation of the nucleophosmin (NPM1) gene (in approximately 35% of the cases).
Other examples of genetic aberrations found in AML with a normal karyotype are
mutations in the tyrosine kinase receptor c-KIT and the GTPases N-RAS and K-RAS.
However, c-KIT as well as RAS mutations do not show any correlation with clinical
outcome in AML (Care et al., 2003; Kiyoi et al., 1999; Neubauer et al., 1994).
Unfortunately, not all mutations in this group could be detected by conventional
cytogenetic methods. For this reason, the development of new molecular methods is
important for the classification of different chromosomal aberrations and for better
understanding of the pathogenesis of this disease and development of innovative
therapeutic strategies.
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1.3.3 FMS-like tyrosine kinase 3 (FLT3) and
          Loss of heterozygosity (LOH)
FLT3 (Fms-like tyrosine kinase 3) also known as FLK-2 (fetal liver kinase 2) and
STK-1 (human stem cell kinase 1) is a type III receptor tyrosine kinase plays a key
role in haematopoiesis (Gilliland and Griffin, 2002a; Kottaridis et al., 2003; Stirewalt
and Radich, 2003). FLT3 expression occurs primarily in immature myeloid and
lymphoid progenitors, including CD34+ cells with high levels of CD117 (c-KIT)
expression (Rasko et al., 1995; Rosnet et al., 1996). Furthermore FLT3 is also
expressed at high levels in a spectrum of haematologic malignancies, including 70-
100% of AML of all FAB subtypes, B-precursor cell acute lymphoblastic leukaemia
(ALL), a fraction of T-cell ALL, and chronic myelogenous leukaemia (CML) in
lymphoid blast crisis. However, the recent data indicate that FLT3 expression could
be involved in the survival, proliferation and differentiation of primitive hemopoietic
progenitor cells (Carow et al., 1996; Drexler, 1996).
FLT3 gene is localised on the chromosome 13q12 (Gilliland and Griffin, 2002b).
FLT3 receptor contains five extracellular Ig-like domains, a transmembrane domain,
a juxtamembrane domain and two tyrosine-kinase domains that are linked through
the tyrosine-kinase insert (Small et al., 1994) The extracellular part is responsible for
the ligand binding. (van der Geer et al., 1994). After the binding of FLT3-Ligand (FL)
conformational changes in FLT3 promote dimerization, phosphorylation and adaptor-
protein docking, transmitting signals to downstream effectors (Fig.1.2). This results in
subsequent activation of several signalling pathways involved in the cell growth and
proliferation.
Constitutively activating mutations of FLT3 are one of the most common genetic
abnormalities in AML. FLT3 mutations cause ligand-independent receptor
dimerisation and constitutive activation (Kiyoi et al., 1998). The mutations involve
more often an internal tandem duplication (ITD) of the juxtamembrane domain and
the result is an activation of STAT5 (Zhang et al., 2000), Ras/mitogen-activated
protein kinase (MAPK) and phosphatidylinositol 3 kinase (PI3K)/AKT pathways
(Hayakawa et al., 2000; Mizuki et al., 2000).
A FLT3-ITD mutation within the juxtamembrane domain of FLT3 was found in about
25 - 30% of AML patients (Nakao et al., 1996). The presence of the FLT3-ITD
mutation is generally associated with a statistically significant poor clinical outcome
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compared with patients not harbouring this aberration. In fact, three distinct
genotypes have been identified in AML patients: normal FLT3WT/WT, heterozygous
FLT3ITD/WT, and hemizygous FLT3ITD/- - FLT3-ITD-positive that also lacked the FLT3
wt allele. The loss of the WT allele is also known as Loss of heterozygosity (LOH).
LOH is a form of allelic imbalance that can arise via several pathways, including
deletion, gene conversion, mitotic recombination and chromosome loss. If FLT3ITD/-
genotype is detected in patients with normal karyotype, the two copies of
chromosome 13 indicate that the loss of the wt FLT3 allele is not a result of a
monosomy 13, or a cytogenetically detectable deletion involving band 13q12 also.
Results of LOH studies suggest that there are two possible explanations of the
FLT3ITD/- genotype in the patients with normal karyotype. The first one is, that
submicroscopic deletion of 13q12 is responsible for the observed wt FLT3 allele loss.
The second is that the whole chromosome 13 with a wt allele could have been
initially lost and later replaced by a duplicated copy of the chromosome 13 containing
the FLT3-ITD allele (thus generating a FLT3ITD/ITD genotype). This process is known
as uni-parental disomy (UPD). In UPD, one allele or an entire chromosome from one
parent are missing leading to the reduplication of the other parental allele (uni-
parental = from one parent, disomy = duplicated).
Recent studies have reported that the FLT3ITD/- patients have a significantly
shortened survival compared with FLT3WT/WT and/or FLT3ITD/WT patients. It has been
suggested that FLT3-ITD arises via a slippage-repair mechanism (Kiyoi et al., 1998),
but the mechanism leading to the loss of the wt FLT3 allele is currently unknown.
Fig 1.2 Mechanism of FLT3 activation (Blume-Jensen and Hunter, 2001).
Left: inactive Form; Right: Ligand-dependent dimerisation and autophosphorylation.
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Not only chromosome 13 can be affected by LOH. This mechanism commonly
occurs in cancer and is associated with the absence of a functional tumor suppressor
gene in the lost region. Despite this, many people remain healthy with such a loss,
because there is still one functional gene left on the other chromosome of the
chromosome pair. However, the remaining copy of the tumor suppressor gene can
be inactivated by a point mutation, leaving no tumor suppressor gene with protection
function. Subsequently this mutation can be duplicated -UPD. Recently it has been
speculated that UPD found in the AML patients is associated with the up regulation of
some genes´ coding proteins involved in the DNA repair process. Loss of
heterozygosity and UPD respectively can be identified using polymorphic markers,
such as single nucleotide polymorphisms, explained in more details below.
1.3.4 "Two hits" model of leukaemogenesis
A majority of authors defend the theory that AML cannot be induced by just one
mutation (Fenske et al., 2004; Kelly et al., 2002; Yuan et al., 2001). They agree that
for AML development the co-operation of a minimum of two mutations is necessary.
These mutations are subdivided in two classes. One class of mutations (class I)
(FLT3 or c-KIT) confers a proliferative or survival advantage to cells, and a second
class of mutations (class II) (AML1-ETO or PML/RARα) serves primarily to interfere
with haematopoietic differentiation and subsequent apoptosis of cells. This model
predicts that only one mutation in each class would be required for AML
development. Together, both transformations induce disruption in the proliferation
and differentiation of both stem- and progenitors cells, and are thus responsible for
the development of AML (Fig 1.3).
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Fig.1.3 Model of the two classes of mutations responsible for the development of AML
(Gilliland and Griffin, 2002a).
1.4 Genome instability and repair
DNA is subjected to spontaneous instability and decay. In addition to spontaneous
damage, cellular DNA is under constant attack from reactive chemicals that the cell
itself generates as by-products of metabolism. Moreover, the integrity of cellular DNA
is assaulted by such environmental threats as X-rays, ultraviolet radiation from the
sun, and many chemical agents, some of which are products of our industrialised
society.
Approximately 104 spontaneous molecular lesions are known to occur in every
human cell every day, mostly by oxidation, hydrolysis, alkylation, radiation, or toxic
chemicals (Fortini et al., 2003). The result can be gene mutations that are further
transferred to the gene product (protein). If these mutations are in genes that
normally control cell proliferation or suppress tumour growth, the cells may start to
grow uncontrollably. Cells have therefore developed mechanisms to repair DNA
damage. Individuals with inherited disorders of DNA repair display increased levels of
chromosomal aberration and mutation in somatic cells, and a predisposition to
cancer (Karran et al., 2003). The rate of DNA repair is dependent on many factors,
including the cell type age, and the extracellular environment. There are four
mechanisms leading to error free repair of DNA damage: Base Excision Repair
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(BER), Nucleotide Excision Repair (NER), Mismatch repair (MM) and Homologous
Recombination (HR).
Other mechanisms of repair are Non-Homologous End Joining (NHR) and Single
strand annealing (SSA). However, NHR and SSA often lead to the loss of genetic
information resulting in DNA damage.
Excision repair, explained in more details below, removes lesions that affect only one
DNA strand. It involves excision of the lesion and subsequent use of the
complementary strand to fill the gap.
1.4.1 Base Excision Repair (BER)
DNA's bases may be modified by deamination or alkylation as a result of oxidative
processes (e.g. ionizing radiation). These mutations are repaired by BER. The
position of the modified (damaged) base is called the "abasic site" or "AP site". The
repair process starts with the enzymatic removal of the AP site and of neighbouring
nucleotides by DNA glycosylases, that can recognize the AP site. The BER
mechanism can proceed through two different subpathways: the short-patch BER
and the long-patch BER. The short-patch BER sub-pathway is characterized by the
insertion of a single base at the lesion site by DNA polymerase ß (Pol ß). The long-
patch Pol ß or the replicative Pol δ/ε re-synthesize an oligonucleotide by 2-7
nucleotides. The long patch also requires PCNA, which is a loading clamp for the
replicative polymerases, and a flap-endonuclease, FEN1, that recognises and
cleaves at the base of the flap structure. The gap is filled by DNA polymerase I and
DNA ligase (Fortini et al., 2003; Hung et al., 2005; Hung et al., 2005). No human
disorders have been related directly to inherited BER deficiencies, and knockout
mice that lack core BER proteins die as embryos, attesting to the important role of
the BER process (Fortini et al., 2003) (Fig.1.4)
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Fig.1.4 Base Excision Repair (BER) and the short and long patch sub-pathways.
Modified from  Minoru Kanehisa (Kanehisa Laboratories).
1.4.2 Nucleotide Excision Repair (NER)
Nucleotide excision repair recognizes a wide range of substrates, including damage
caused by UV irradiation (pyrimidine dimers and 6-4 photoproducts) and chemicals
(intrastrand cross-links and bulky adducts). This process consists of recognition of
the damaged DNA, excision of an oligonucleotide of 24 – 32 residues containing the
damaged DNA. The gap is then filled by DNA polymerase I and DNA ligase  (Costa
et al., 2003; Batty, and Wood, 2000; de Laat et al., 1999; Friedberg, 2001).
nucleotide excision repair can be categorized into two classes, global genome NER
(GG-NER) and Transcription Coupled NER (TCR-NER)
The GG-NER surveys the entire genome for lesions which distort the DNA. In this
sub-pathway the DNA disorder is recognised by the XPC-hHR23B Complex (Fig.1.5).
The TCR-NER focuses on DNA lesions that block the activity of RNA polymerases
and the overall transcriptional activity, and rapidly repairs damage on the transcribed
strand of active genes (Fig.1.5) (Costa et al., 2003; Hoeijmakers 2001; Benhamou
and Sarasin, 2000). In this sub-pathway, stalled RNA polymerase II acts as a marker
for lesion recognition by CSA/CSB.  In both pathways a nine-subunit complex (TFIIH)
Oxidized or ring-saturated base Deaminated, alkylated or mismatched base
Glycosylase
APEX
Short patch BER
Long patch BER
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of helicases carry out DNA unwinding. The RPA stabilizes the unwound DNA, and
XPA assembles DNA repair factors. The damaged DNA is then removed by XPG and
the XPF-ERCC1 complex, which make 3´ and 5´ incisions. The gap is filled by DNA
polymerase δ/ε and sealed by DNA ligase (Fig.1.5)
Fig.1.5 Nucleotide excision repair of a bulky adduct. Modified from  Minoru Kanehisa
(Kanehisa Laboratories).
1.4.3 Mismatch repair (MMR)
The DNA mismatch repair (MMR) pathway has been evolved to correct errors made
by DNA polymerase during DNA replication. Such errors fall into two broad
categories: base substitutions and insertions/deletions. A base substitution error
occurs when the DNA polymerase inserts an incorrect (noncomplementary)
nucleotide opposite the template base. Often, DNA polymerase will make a base
substitution error when copying a base that has been damaged by alkylation. An
insertion error occurs when the DNA polymerase adds one or more extra nucleotides
to a sequence. A deletion error is made when one or more nucleotides are omitted
from a sequence.
The process of MMR, like the BER and NER pathways, comprises damage
recognition, damage excision, DNA repair synthesis, and DNA ligation. Mismatch
repair is a highly conserved process from prokaryotes to eukaryotes. The first
GG-NER TCR-NER
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evidence for mismatch repair was obtained from S. pneumoniae. Subsequent work
on E. coli has identified a number of genes wich gene products are therefore called
the "Mut" proteins, and are the major active components of the mismatch repair
system. Three of these proteins are essential in detecting the mismatch and directing
repair machinery to it; MutS, MutH and MutL. The human MMR protein family
members responsible for recognition of mispaired DNA are termed hMSH, for human
MutS Homologs. MutS heterodimer recognises a mismatch (Fig.1.6.1) and MutL
heterodimer is recruited (Fig.1.6.2). The MutS sliding DNA clamps can migrate in
either direction. MutL works as a matchmaker, displacing the PCNA/DNA polymerase
complex when encountered (i.e. when the DNA clamp moves in 5´>3` direction)
(Fig.1.6.3). The MutL complex in humans is a heterodimer consisting of hMLH1 and
hPMS2 proteins.
MutH is a very weak endonuclease that is activated once bound to MutL (which itself
is bound to MutS). MutH has no eukaryotic homolog. Its endonuclease function is
taken up by MutL homologs, which have some specialized 5'-3' exonuclease activity.
MutL recruits exonuclease 1 (Exo I) that excises up to a kilobase of DNA at the site
of the mismatch (Fig.1.6.4). The error is corrected by re-synthesis.
Fig.1.6 Repair of a single nucleotide mismatch. Modified from Jascur and Boland,
2006.
1.5 Double-Strand Break (DSB)
DSBs are the most serious form of DNA damage because they pose problems for
transcription, replication, and chromosome segregation. DSBs affect both strands of
the DNA duplex and therefore prevent the use of the complementary strand as a
MutL
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template for repair. Cells have evolved two major pathways of DSB repair: HR
(Homologous Recombination) and NHEJ (Non-Homologous End Joining). When two
repeated sequences are very close to each other, SSA (Single Strand Annealing) is
another possible mechanism of repair.
In this project I concentrated on DSB repair. For this reason, the repair processes
involved in this mechanism will be explained in more details below.
When DSBs are generated, independent of the repair mechanism (HR NHEJ or
SSA), ATM is activated and relocated through an interaction with the
RAD50/MRE11/NBS1 complex. In the next step, ATM phosphorylates histone H2Ax
in the chromatin micro-environment surrounding a DNA double-strand break (DSB).
Afterwards, different signalling pathways are involved in these three repair
mechanisms.
1.5.1 Non-Homologous End Joining (NHEJ)
NHEJ seems to be the primary mechanism of DSBs repair in mammalian cells
(Jeggo et al., 1998). Conceptually, the mechanism of NHEJ is simple—the broken
ends are brought together and then joined. If the cell incurs more than one DSB, then
previously unlinked DNA molecules may be joined, resulting in gross chromosomal
rearrangements. The binding of specific protein factors to the broken ends is the first
step in NHEJ. This serves to limit nucleolytic degradation, which would result in the
loss of genetic information. Using genetic studies of mammalian cell lines, several
proteins involved in the DSB repair process were identified (Jeggo et al., 1991; Lees-
Miller et al., 1995; Gu et al., 1997; Riballo et al., 1999).
One of the most important proteins in NHEJ in mammalian cells is the Ku complex,
which is a heterodimer of Ku70 and Ku86 (also known as Ku80) and is the major
DNA end binding factor in mammalian cells. The Ku complex recruits DNA-PKcs
(DNA-dependent protein kinase catalytic subunit) to the DSBs, activating its kinase
function (Weaver et al., 1996; Chu et al., 1997; Critchlow & Jackson, 1998). It has
been proposed that DNA-PKcs has an impact on the XRCC4/DNA and ligase IV
heterodimer, factors that are also important for NHEJ (Critchlow et al., 1997;
Grawunder et al., 1997; 1998). However, the precise roles of these proteins in the
repair process are unknown. Three possible steps have been suggested for the
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repair of DSBs by NHEJ: 1. end-binding and bridging, 2. terminal processing, and 3.
ligation.
The Ku heterodimer initiates NHEJ by binding to the free DNA ends, thus protecting
from degradation and recruiting other NHEJ factors such as DNA-PK, XRCC4, and
DNA Ligase-IV (Cary et al., 1997; Pang et al., 1997; Yaneva et al., 1997; Feldmann
et al., 2000). DNA-PK becomes activated upon DNA binding, and phosohorylates a
number of substrates including p53, Ku, and XRCC4. (Mahajan et al., 2002). The
phosphorylation of these factors further facilitates the repair process. Because the
ends of most DSBs generated by genotoxic agents are damaged and are unable to
be directly ligated, they often have to undergo limited processing by nucleases and/or
polymerases before NHEJ can proceed. This process includes the MRE11-RAD50-
NBS1 complex, that has  exonuclease and helicase activities (Paull et al., 1998;
Khanna et al., 2001). RAD50, MRE11 (Meiotic Recombination-11) and NBS1
(Nijmegan Breakage Syndrome-1) function particularly if the DNA ends require
processing before ligation. The final step in NHEJ repair involves ligation of the DNA
ends by Ligase-IV in a complex that also includes XRCC4 and Ku. (Junop et al.,
2000; Lee et al., 2000; Sibanda et al., 2001) (Fig.1.7).
Fig.1.7 Repair of DNA double strand breaks by non-homologous end joining. Adapted
from Kobayashi et al., 2004.
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1.5.2 Single strand annealing (SSA)
Single strand annealing (SSA) is a process initiated when a double strand break is
made between two repeated sequences oriented in the same direction. Single
stranded regions are created adjacent to the break, and they extend along the
repeated sequences, so that the complementary strands can anneal to each other.
This annealed intermediate part can be processed by digesting away the single
stranded tails and filling in the gaps.
SSA requires several gene products that are also necessary for other types of
recombination assays. RAD52, for example, is important for most if not all types of
recombination processes that include SSA. RAD52 is a DNA binding protein that can
anneal ssDNA in vitro (Mortensen et al., 1996, Shinohara et al., 1998). A homolog of
RAD52, RAD59 is also required for SSA and has DNA binding properties and strand
annealing activity.
Another pair of proteins that exhibit homologous sequence length dependence during
SSA comprises MSH2 and MSH3 (Sugawara et al., 1997). These proteins, along
with the RAD1-RAD10 excision endonuclease protein complex (Fishman-Lobell and
Haber 1992), are involved in removing nonhomologous 39-ended DNA tails from
annealed intermediates. However, whereas RAD1 and RAD10 are required to clip off
the tails regardless of the length of the annealed homologous regions, the
requirement for MSH2 and MSH3 decreases dramatically as the annealed regions
increase from 205 bp to 1.17 kb. Interestingly, MSH2 and MSH3 are also needed for
the removal of nonhomologous sequences from the ends of the invading strands
during DSB-induced gene conversion, even when the length of homologous
sequence shared by the donor and recipient is 2 kb (Paˆques and Haber 1997). They
presumably act in a similar manner, by binding to the junctions between single-
stranded DNA and double-stranded DNA and promoting the RAD1- RAD10 -
mediated cleavage of the single-stranded nonhomologous tail, so that the 39 end of
the invading DNA strand can be used as a primer to initiate new DNA synthesis. The
need for MSH2 and MSH3 in gene conversion, even with long homologous regions
adjacent to the nonhomologous ends, presumably reflects the difference between the
instability of a strand invasion structure (involving an invading single strand and a
duplex template) and the more stable intertwining of two complementary single
strands during SSA (Fig.1.8).
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Fig.1.8 Repair of DNA double strand breaks by single strand annealing. Adapted from
Kristoffer and Lawrence  2003.
1.5.3 Homologous Recombination (HR)
In the process of HR, a DSB is repaired by copying the missing information from the
sister chromatid or homologous chromosome, resulting in the exact restoration of the
DNA. HR is the main pathway for postreplicative repair during the late S/G2-phase.
One of the earliest events in HR-dependent repair is converting the DSB ends to a
recombination competent structure. This step involves degradation of single strands
by the eukaryotic MRE11/RAD50/NBS1 (MRN) complex leaving a 3’ protruding end,
which is hundreds of bases long (Fig.1.9B) (Krogh and Symington, 2004). The
resulting 3´ ssDNA tails are bound by RPA (1.9C), which is replaced with RAD51 in a
reaction mediated by RAD52 and RAD51 paralogues (1.9D) (Sung 1997; Shinohara
and Ogawa 1998). Subsequently, this nucleoprotein filament invades the intact DNA
duplex, and forms a structure called the “D-loop”. Strand displacement and branch
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migration are complicated tasks and involve many energy-dependent processes,
such as breaking internal hydrogen bonds, unwinding the DNA, and competing with
other DNA binding proteins (Fig.1.9E). Hence, many proteins play roles during these
processes, including RAD51, and all five RAD51-like proteins, namely XRCC2,
XRCC3, RAD51B (or RAD51L1), RAD51C (RAD51L2) and RAD51D (RAD51L3)
(Albala et al., 1997; Rice et al., 1997; Cartwright et al., 1998; Dosanjh et al., 1998;
Liu et al., 1998; Pittman et al., 1998; French et al., 2002). These RAD51 paralogues
form four different complexes, XRCC2-RAD51D, RAD51B-RAD51C, XRCC3-
RAD51C and RAD51B-RAD51C-RAD51D-XRCC2, that stimulate the activity of
RAD51 in various aspects (Braybrooke et al., 2000; Kurumizaka et al, 2001;
Sigurdsson et al., 2001; Henry-Mowatt et al., 2003; Yokoyama et al., 2003). Other
relevant proteins include: RAD54, RAD54 paralogues, and the breast cancer
associated proteins BRCA1/2 (Jasin 2002). RAD54 likely has a dual function both in
enabling strand exchange and in facilitating branch migration. It can stabilize RAD51
nucleofilament and enhance D-loop formation by introducing negative supercoils (1.9
D-F) (Sigurdsson et al., 2002; Mazin et al., 2003). Normal basepairing follows after
the dissociation of RAD51 from ssDNA of the invading and complementary donor
strands and subsequent strand extension by DNA polymerase. The extended strand
can dissociate and anneal with the processed end of the non-invading strand on the
opposite side of the DSB in a process called synthesis- dependent strand annealing.
Alternately, both ends may invade, producing a double-holiday junction that is
resolved to yield crossover or non-crossover recombination. Once intermediates are
resolved, possibly by the action of XRCC3/RAD51C complex (Fig.1.9G) (Brenneman
et al., 2002; French et al., 2002; Liu et al., 2004), the remaining ssDNA gaps and
nicks are repaired by DNA polymerase and DNA ligase.
Crossovers are associated with a fraction of HR events and can have a stabilizing or
destabilizing effect on the genome. In meiosis, crossovers are highly regulated such
that at least one crossover occurs between each pair of homologous chromosomes
to ensure proper chromosome segregation, while excess crossovers are suppressed
(Champion et al., 2002). In mitosis, crossover poses serious risks of large-scale
genome alterations: half of the G2 phase crossovers between homologous result in
loss of heterozygosity from the point of the crossover to the telomere, and crossover
between repeated regions on non-homologous chromosomes, the same
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chromosome, or sister chromatides can result in translocations, inversions, deletions,
and UPD (Nickoloff 2002). All these increase genome instability
Fig.1.9 Repair of DNA double strand breaks by Homologous Recombination. Modified
from Jackson 2001; 2002.
1.6 Polymorphism
A polymorphism is a geremline variation in the base sequence of the genetic
code, defined by inheritable variations present at an allele frequency higher than 1%
in the general population. At lower frequencies it is termed a germline mutation
(Strachan and Read 1996). Polymorphisms are not associated with diseases, unlike
mutations. The polymorphisms can remain and spread within a population, either
because they have no major effect or because they are associated with beneficial
effects for individuals. Some mutations tend to be selected against by evolution, even
if they do not disappear completely, and they may arise spontaneously in new
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generations. Also, some deleterious mutations persist in populations because they
are associated with a selective advantage under certain environmental conditions.
Polymorphisms and germline mutations are present in the genetic code of every cell
of an individual. Furthermore, non-inheritable alterations acquired during the lifetime
of an individual are present in the genetic code. These are known as somatic
mutations and are present within the affected tissue only. Thus, somatic mutations
can proliferate by clonal expansion of the mutated cell, but cannot be transmitted to
the offspring of the affected individual.
The most common type of polymorphisms in the human genome are single
nucleotide polymorphisms (SNPs). Previous estimates suggest that there may be ~ 5
million SNPs with minor allele frequencies of at least 10%, possibly as many as ~ 10
million with major allele frequencies of at least 1% (Kruglyak and Nickerson 2001).
The Human Genome Project has provided a windfall of sequence polymorphism
data, and because of collaborative SNP discovery initiatives such as the SNP
Consortium (TSC), millions of human SNPs have been catalogued. The mapping of
these SNPs is an excellent genotypic marker for research. Recently, SNP arrays
were developed to analyse polymorphisms and to study the whole genome within a
population. A very important application of SNP array is in determining disease
susceptibility and consequently, in pharmacogenomics, by measuring the efficacy of
drug therapies specifically for each individual. As a result, drugs can be personally
designed for more efficiency on a group of individuals who share a common allele, or
even for a single individual.
Furthermore, a SNP array can be used for studying the loss of heterozygosity
(LOH), which includes not only genomic gains or deletions, but can also detect copy
number neutral LOH due to uniparental disomy (UPD). The use of a high density
SNP array for LOH detection allows the identification of pattern of allelic imbalance
with potential prognostic and diagnostic utilities. This has a huge potential in cancer
diagnosis, as LOH is a prominent characteristic of most human cancers. Recent
studies based on the SNP array technology have shown that not only solid tumours
(e.g. gastric cancer, liver cancer etc) but also haematological malignancies (ALL,
AML, MDS, CML etc) have a high rate of LOH due to either genomic deletions or
UPD and genomic gains. The results of these studies may help to gain insights into
mechanisms of these diseases and to create targeted drugs.
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1.7 Aim of the project
Acute myeloid leukaemia is a very heterogenous disease which is associated with
diverse cytogenetic abnormalities like chromosomal deletions, translocations and
duplications. The diagnosis of the karyotype is one of the most important factors to
determine the outcome of this disease, but only in 50% of patients the genetic
background of cancer development could be found. In the remaining group normal
karyotype has been detected. With current methods it is very difficult to understand
the mechanisms of AML progression in this group. However, some genetic
aberrations were reported like point mutations in FLT3 gene, inactivating mutations in
transcriptionfactors CEBPA and one of the most common mutations in the NPM1-
gene. Recently it was also reported about UPD (uniparental disomy) in connection
with AML. Little is known about the mechanisms of UPD and what connection this
aberration has with the outcome of this disease. In particular, in this project the
following tasks were proposed:
1. Screening of larger panels of patients for LOH
2. Identification of chromosomal location of UPD
3. Identification of genes affected by this mutation
4. Identification of links between LOH and disease outcome
5. Explore the mechanism of UPD
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2. Materials and Methods
2.1. Laboratory equipment
Laboratory Centrifuges 4-15 C Qiagen, Hilden, Germany
Centrifuge 5810R Eppendorf, Germany
Centrifuge 5417C Eppendorf, Germany
BioRobot 8000 Qiagen, Hilden, Germany
Vortex REAX top Heidolph, Schwabach, Germany
Thermoblock Eppendorf, Germany
Thermoblock Liebisch Labortechnik, Bielefeld,
Germany
Laborpipetts: Gilson, Middleton, USA
Anthos htII spectrometer Anthos Labtec Instruments, Wals,
Australia
NanoDropTM 1000 Spectrophotometer Thermo scientific, Germany
GeneAmp PCR System 9700 Applied Biosystem, Foster City, USA
GeneAmp PCR System 2400 Perkin Elmer, Germany
Mastercycler epgradients Eppendorf, Germany
Vortex REAX 2000 Heidolph, Schwabach, Germany
Minicentrifuge Fischer Scientific, Schwerte, Germany
Facs Calibur Becton Dickinson, Heidelberg, Germany
FacsVantage SE Becton Dickinson, Heidelberg, Germany
FACSAria Beckton Dickinson, Heidelberg, Germany
CO2 water – Jacketed Incubator
US AUTO FLOW
Nuaire, Plymouth, USA
Inkubator 1000 Heidolph, Schwabach, Germany
G.F.L. Shaking Incubator 3033 Progen Scientific Ltd, Mexborough,UK
Biometra TI 3 Polaroid, Germany
Horizon 11-14 gel electrophoresis
apparatus
GIBCO BRL, Karlsruhe, Germany
Electrophoresis power supply ST 606 T Gibco BRL, Karlsruhe, Germany
ABI 377 Applied Biosystems, Darmstadt, Dermany
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ABI PRISM 3130X/ Genetic Analyzer Applied Biosystems, Darmstadt, Dermany
GloMax™ 96 Plate Luminometer Promega GmbH, Germany
GeneChip® Fluidics Station 450 Affymetrix, Germany
GeneChip® Hybridization Oven Affymetrix, Germany
GeneChip® Scanner 3000 Affymetrix, Germany
PH-Meter WTW, Weilhem, Germany
Epifluorescence microscope Nikon
Eclipse TS100
Nikon, New York, USA
Light microscope Nikon eclipse TS 100 Nikon, New York, USA
Leica SP5 inverse confocal microscope Leica Microsystems, Wetzlar, Germany
XE-2100 Sorter Sysmex, Germany GMBH
7500 Real Time PCR System Applied Biosystems, Darmstadt, Dermany
Anthos htII spectrometer Anthos Labtec Instruments, Wals,
Australia
2.2 Chemicals and reagents
2.2.1 Fine chemicals
Ethanol Prolabors, Georgsmarienhütte, Germany
Methanol Merck, Darmstadt, Germany
Isopropanol Merck, Darmstadt, Germany
Acrylamid Sigma, München, Germany
Ethidiumbromid Roth, Karlsruhe, Germany
37% formaldehyde solution Merck, Darmstadt, Germany
Acetic acid Merck, Darmstadt, Germany
Ampicillin Gibco BRL, Karlsruhe, Germany
Kanamycin Gibco BRL, Karlsruhe, Germany
Puromycin Gibco BRL, Karlsruhe, Germany
Zeocyn Invitrogene, Karlsruhe, Germany
Agarose Gibco BRL, Karlsruhe, Germany
Sephadex Gibco BRL, Karlsruhe, Germany
BactoTM-Tryptone Becto Dickinson, sparks, USA
BactoTM- yeast extract Becto Dickinson, sparks, USA
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Loading buffer Promega GmbH, Germany
Penicillin/Streptomycin PAA, Pasching, Australia
FBS (Fetal Bovine Serum)                                 Gibco BRL, Karlsruhe, Germany
RPMI 1640 Gibco BRL, Karlsruhe, Germany
DMSO Sigma, München, Germany,
Phosphate Buffer Saline (PBS) PAA, Pasching, Australia
BSA (Bovine Serum Albumin): New England Biolab, Ipswich, MA
dNTP Invitrogene, Karlsruhe, Germany
Dextran Blue Fluka, Buchs, Switzerland
5M TMACL (Tetramethyl Ammonium
Chloride)
Sigma, München, Germany
Tween-20 SERVA, Heidelberg, Germany
MES hydrate Sigma, München, Germany
MES Sodium Salt Sigma, München, Germany
R-Phycoerythrin Streptavidin Molecular Probes
Denhardt’s Solution Sigma, München, Germany
HSDNA (Herring Sperm DNA) Promega GmbH, Germany
Human Cot-1 Invitrogen, Karlsruhe, Germany
20X SSPE (3M NaCl, 0.2M NaH2PO4,
0.02 M EDTA)
BioWhittaker, Maine, USA
5M NaCl, RNase-free, DNase-free Ambion, Austin, USA
5X 1st Strand Reaction MixL Invitrogen, Karlsruhe, Germany
5X 2nd Strand Reaction Mix Invitrogen, Karlsruhe, Germany
DTT, 0.1M Invitrogen, Karlsruhe, Germany
Formamid Sigma, München, Germany
Glycerol Sigma, München, Germany
SephadexTMC50 Fine Amersham, Uppsala, Sweden
SOC medium Invitrogen, Karlsruhe, Germany
Tris Roth, Karlsruhe, Germany
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2.2.2 Enzymes and PCR reagents
Eco RI New England Biolabs, Ipswich, MA
SacI New England Biolabs, Ipswich, MA
HindIII New England Biolabs, Ipswich, MA
AmpliTaq gold DNA polymerase Applied Biosystem, Darmstadt, Dermany
10xPufer with MgCl2 New England Biolab, Ipswich, MA
MgCl2 Applied Biosystems, Darmstadt, Dermany
SS RT Promega GmbH, Germany
Xba I (20,000 U/mL):: New England Biolab, Ipswich, MA
T4 DNA Ligase: New England Biolab, Ipswich, MA
SuperScript II Invitrogen, Karlsruhe, Germany
E. coli DNA ligase Invitrogen, Karlsruhe, Germany
E. coli DNA Polymerase I Invitrogen, Karlsruhe, Germany
RNase H Invitrogen Invitrogen, Karlsruhe, Germany
T4 DNA Polymerase Invitrogen, Karlsruhe, Germany
2.3 Kits
HiSpeed Plasmid Maxi kit (25) Qiagen, Hilden, Germany
QIAprep Spin Miniprep kit (250) Qiagen, Hilden, Germany
Dye Ex 2.0 Spin kit Qiagen, Hilden, Germany
QIAquick PCR Purification kit Qiagen, Hilden, Germany
TOP10 Chemically Competent E. coli Invitrogen, Karlsruhe, Germany
One Shot® TOP10 E. coli Invitrogen, Karlsruhe, Germany
DH5α™ Cells Invitrogen, Karlsruhe, Germany
TOPO TA Cloning® Invitrogen, Karlsruhe, Germany
QIAamp DNA Blood Midi Kit Qiagen, Hilden, Germany
QIAamp RNA Blood Mini Kit Qiagen, Hilden, Germany
H2A.X Phosphorylation Assay Kit Upstate; Millipore, Schwalbach/Ts,
Germany
REPLI-g Kit Qiagen, Hilden, Germany
Genomiphi DNA Amplification kit Amersham; Uppsala, Sweden
CD3 MicroBeads Miltenyi biotec, Bergisch Gladbach,
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Germany
Humantype Chimera PCR Amplification kit Biotype, Dresden, Germany
GeneChip® Human Mapping 10K Xba 131 Array Affymetrtix, Germany
GeneChip® Human Mapping 10K Xba 142 Array Affymetrix, Germany
GeneChip® Human Mapping 10K Xba 131 Kit Affymertix, Germany
GeneChip® Human Mapping 10K Xba 142 Kit Affymetrix, Germany
GeneChip® Human Genome U133A Array Affymetrix, Germany
MinElute 96 UF PCR Purification Kit: Qiagen, Hilden, Germany
Each T7-Oligo(dT) Promoter Primer Kit Affymetrix, Germany
BioArray™ HighYield™ RNA Transcript Labeling
Kit (T7) ENZO, Farmingdale, NY
GeneChip® Sample Cleanup Module Affymetrix, Germany
GeneChip Eukaryotic Hybridization Control Kit Affymetrix, Germany
Power SYBR® Green PCR Master Mix Applied Biosystem, Foster City, CA,
USA
Big Dye Terminator v 3.1 cycle sequencing kit Applied Biosystem, Foster City, CA,
USA
2.4 Antibodies
Antibodies used in this work were diluted and stored according to supplier’s
information.
Primary antibodies
RAD51 antibody (Mouse) GeneTex, Hiddenhausen, Germany
Secondary antibodies
Goat anti-mouse IgG/HRP Dako Cytomation, Glostrup, Denemark
Anti-streptavidin antibody (goat),
biotinylated,
Vector Laboratories, Burlingame, CA
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2.5 Nucleic acids
2.5.1 Acquired plasmids
Table 2.1 An overview of the reporter plasmids used in this work.
Restriction map of the plasmids can be found in the results section (chapter 3.2.6.1).
Plasmid Genetic
markers
Description Reference
pmHPRT-DRGFP Ampr Contains DR-GFP repotrer with I-Sce
I cleavage site
Generous gift of
Maria Jasin, Sloan-
Kettering Cancer
Center (New York
USA)
pCbASce Ampr Contains I-Sce I endonuclease Generous gift of
Maria Jasin, Sloan-
Kettering Cancer
Center (New York
USA)
2.5.2 Synthetic oligonucleotides
The tables above represent a list of synthetic oligonucleotides used in this work.
All oligonucleotides were purchased from TiB MolBiol (Berlin).
Table 2.2 Primer using for STR analyses to confirm LOH
Chromo
some
Name Forward primer Reverse primer Physical Position
Chr.1 D1S2724 TGTGAAGCCACATTTTCCAA TGTTCTGCTTGGCACTTTTG 47353920-47354196
Chr.1 D1S2843 GGGCTGGGCATTACACAAC ATCAAATTGGCTTCTCACCG 18756299-18756477
Chr.1 D1S2644 TGCAACCCACCTGAATGA TACGTGAAGTGCCAGCACA 17272558-17272774
Chr.1 D1S238 TCATGTCTAGATCCTGTGCC TGGAGGCAGTTTAGATTGTG 159380623-159380922
Chr.1 D1S1660 TGCTATCCTCTCACCAGTGA GTCTGAAGTTCATGGGAACG 169778575-169778814
Chr.2 D2S2153 CCTCAGGGACTTGGTTTAACAG CCTTTGGGAAATGCTGATTG 54440636-54440786
Chr.2 D2S378 TGTGGGCTGGTCAGATATTC CGCTAGGATCACTATGTTTTGC 57039502-57039616
Chr.2 D2S2352 TCACGCTGCTGGACTC GGGCAAAATTCGACTCATTA 53610256-53610529
Chr.2 D2S285 TGTAGAAATCACAGGGCAGG CACCACTGCACATGGCTAAT 67384252-67384450
Chr.2 D2S139 AGCTCAAAGCAAATGCATGC AAATTGCGAAACTGTGGCTT 79499062-79499211
Chr.2 D2S387 AGCTCACTTTTGGCCTC TGGATCTTGGATGTTCATTC 19099786-19100000
Chr.3 D3S3695 TTGATTTTGGACTTTTCAGC TGGCACCTGTATGTATGAGA 106495856-106496064
Chr.3 D3S3045 ACCAAATGAGACAGTGGCAT ATGAGGACGGTTGACATCTG 104364610-104364808
Chr.3 D3S3655 GCATTCATACTATGCTAGTTGAGAG ATAATGTTTGCCCACTGGAG 100097895-100098090
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Chromo
some
Name Forward primer Reverse primer Physical Position
Chr.3 D3S1591 TGGAGTCTTCAGCATTTTT TGACATCTATTTACAGATATTAACC 102700083-102700325
Chr.3 D3S2459 CTGGTTTGGGTCTGTTATGG AGGGACTTAGAAAGATAGCAGG 100570538-100570730
Chr.6 D6S1617 TGCAAAACAGGCACACATAC TTAATCAATTTTCTGCAAAGATAAA 4088927-4089040
Chr.6 D6S263 CTTAAGGCAAAATTCTTTTCAACAC CTCAAAGTAAGACCATAAAATACCA 8427239-8427346
Chr.7 D7S2555 AGTTAGCCCATGCCAC GCCAATCAGTTTCAATCTC 80200584-80200707
Chr.7 D7S513 AGTGTTTTGAAGGTTGTAGGTTAAT ATATCTTTCAGGGGAGCAGG 11509549-11509733
Chr.7 D7S820 TGTCATAGTTTAGAACGAACTAACG CTGAGGTATCAAAAACTCAGAGG 78397881-78398094
Chr.8 D8S1477 AGCAAACTTCATCCACTTGG TTCCTGTCCTCTAATGTAACTTACC 30612326-30612495
Chr.8 D8S505 AGCCTGCTATTTGTAGATAATGTTT AGTGCTAAGTCCCAGACCA 32984444-32984650
Chr.8 D8S1694 TGACCAGCACACCACTAAAT TGCTTCAAAATTCTCATTCC 113670715-113670962
Chr.8 D8S1122 GGTGACAGAATCAGACCCTG TGCTCAAATCTGCAATTTCA 105749182-105749310
Chr.11 D11S968 GGCTCTTGTAGTTTCTTATCTCCT AAGGCGGATGCTGGAC 129772991-129773137
Chr.11 D11S976 TCAGTTCAAGTTGCAGAAGAA CAACTTGGTGACAGCCTTTC 113849631-113849750
Chr.11 D11S4107 TCATTCTACAAGACTAGCATTACC GCTTGATCATGGTGTATTATCTT 116989733-116989930
Chr.11 D11S937 CTAATAAACAAATCCCTCTACCTCC TAGTCAGTCAGGGACCCAAGT 74152079-74152342
Chr.13 D13S279 TGGTTTGTTGCAGAAAGCACAC TTGGGCCTTGTCAACCTTCATA 52497146-52497396
Chr.13 D13S1244 TCAACAAGTGGATTAAGAAACTGTG CTGTTTATGGCTGAGAAGTATGC 27144977-27145072
Chr.13 D13S173 CCCTGTTCCAGTAATGATGACC GTCTCTGGCTGCTCTCAAGACTAT 106604948-106605119
Chr.13 D13S1283 AAGTTCACAGTTTTTTAGAGAAACA AGGTTAGGTGAGGGTTGTCT 68615741-68615916
Chr.13 D13S1254 AAATTACTTCATCTTGACGATAACA CTATTGGGGACTGCAGAGAG 26416434-26416657
Chr.19 D19S425 CCACAGGTGTGCATAAAAG GCCATGTGACTGTAGCAGA 32002284-32002550
Chr.19 D19S571 ATTGAGCCACTGAACTCCA TTAGCCAAACTTGACAGCA 49625061-49625282
Chr.20 D20S471 GGGATGCAGAAATTGCAGTA TTTTCTCTTTGCCACTGACC 19779543-19779862
Chr.20 D20S170 TTCTCAGGCTCCTGGC GGGGGCTTCCATGAGT 37052492-37052735
Chr.20 D20S107 CTACATGATGCCTCTTGGGA TCAGACAATGGCAAATTCCT 35593077-35593344
Chr.20 D20S910 AATGATGGAAATAATTCATGTCA CTCTCCACATTGTCGGAT 15097071-15097159
Chr.20 D20S871 GTGAGCCGAGATTATGCC TGCACACTAGAATCCCTTGG 23283573-23283756
Chr.21 D21S265 TTAAAGCAATCAATCATGG GGGTTCTGTGAATATGGG 12102891-12103141
Chr.21 D21S1909 CTGTGATTGTGTTTTCCATTTAGCA TTCCACACTGAGTCAAGAGCAGG 17716281-17716520
Chr.21 D21S2055 AACAGAACCAATAGGCTATCTATC TACAGTAAATCACTTGGTAGGAGA 26388901-26389065
Chr.22 D22S446 CCGGAACTTTGGAAGG CCACTTGGGTAACCACTG 20349158-20349359
Chr.22 D22S1169 GCACACACATGCACATAATC AACAACTTCCAGCAGACG 32346136-32346259
Table 2.3 Primer using for measurment of the expression level of RAD51.
Name Forward primer Reverse primer
Rad51-s GAGGTGAAGGAAAGGCCATGT
Rad51-as GGGTCTGGTGGTCTGTGTTGA
Materials and Methods 32
Table 2.4 Primer using for detection of HR, NHR and SSA.
Name Forward primer Reverse primer Dye Description
HPRTGFP_1 TTCAGATCCGCCGCCACTAT BoTMR Fragment in the
mutated GFP region
HPRTGFP_2 TTGCCGTAGGTATTACCCTGTTAT Fam
HPRTGFP_3 CTCTCCTGACTACTCCCAGT
Fragment in the
intact GFP region
HPRTGFP_4 AGGTGGCATCGCCCTCG Hex
HPRT-NHR TCGTGCTGCTTCATGTGGTC
HPRT-SSA-F1 CTCCTGGGCAACGTGCTGGTT Fam
HPRT-SSA-R2 GCTATGACCATGATTACGCCAAGC
SSA_R TGACCATGATTACGCCAAGC
Primer for the
detection of NHR
Primer for the
detection of SSA
2.6 Patients
146 newly diagnosed de novo AML cases with normal karyotype, the majority of
patients treated according to the AML-96 Deutsche Studieninitiative Leukämie
protocol (DSIL).
2.7 Cell lines
MV4-11 - AML M5 isolated from Patient 10-year-old male;
Karyotype: 48(46-48)<2n>XY, +8, +18, +19, -21, t(4;11)(q21;q23);
Specifics: t(4;11)(q21;q23); MLL-AF4 fusion gene;
Gene alteration: FLT3 ITD (homozygous)
Molm13 - MDS (RAEB)       AML M5a isolated from 20-year-old male
Karyotype: hyperdiploid with 4% polyploidy; 51(48-52)<2n>XY, +8, +8, +8, +13,
del(8)(p1?p2?),ins(11;9)(q23;p22p23)
Specifics: ins(11;9)(q23;p22p23); MLL-AF9 fusion gene (2 different transcripts)
Gene alteration: FLT3 ITD (hererozygoty), P15INK4B deletion, P16INK4A deletion
K562 - CML isolated from 53-year-old female
Karyotype: 61-68<3n>XX, -X, -3, +7, -13, -18, +3mar, del(9)(p11/13), der(14)t(14;?)(p11;?),
der(17)t(17;?)(p11/13;?), der(?18)t(15;?18)(q21;?q12), del(X)(p22)
Specifics: Ph+ t(9;22)(q34;q11); BCR-ABL1 b3-a2 fusion gene
Gene alteration: ABL amplification, P15INK4B deletion, P16INK4A deletion, P53 mutation
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THP1 - AML M5 isolated from 1-year-old male
Karyotype: 94(88-96)<4n>XY/XXY, -Y, +1, +3, +6, +6, -8, -13, -19, -22, -22, +2mar,
add(1)(p11), del(1)(q42.2), i(2q), del(6)(p21)x2-4, i(7p), der(9)t(9;11)(p22;q23)i(9) (p10)x2,
der(11)t(9;11)(p22; q23)x2, add(12)(q24)x1-2, der(13)t(8;13)(p11;p12), add(?18)(q21)
Specifics: t(9;11)(p21;q23); MLL-AF9 fusion gene
Gene alteration: NRAS mutation, P15INK4B deletion, P16INK4A deletion, P53 mutation,
RB1 rearrangement
2.8 Growth media
All media for cultivation of microorganisms were prepared as described below. For
solid media, agar was added to the final concentration of 20 g/l.
LB medium (Luria-Bertani medium)
                                                Final concentration
Pepton                                          1 % (w/v)
Yeast extract                                 0.5 % (w/v)
NaCl                                              1 % (w/v)
Complete media for the cellculture
                                                      Final concentration
RPMI-1640
FCS (Fetal Bovine Serum)                    10%
Penicillin/Streptomycin                          1%
2.9 Cell sorting of CD3 (T-cells) and CD33; CD34 and CD117 (Blasts)
Max puffer: 500ml PBS
                   16ml 20% Albumine
                   55ml Citrate Solution
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The frozen cells (–800C) were warmed briefly and carefully added to 10ml Max.
Buffer, followed by centrifugation at 300xg for 10 min. The cells were resuspended in
a buffer and magnetically labelled with 20 µl CD3 MicroBeads. Then the cell
suspension was loaded onto a MACS® Column which was placed in the magnetic
field of a MACS Separator. The magnetically labelled CD3+ cells were retained on
the column. The unlabeled cells were run through and this cell fraction was depleted
of CD3+ cells. After removal of the column from the magnetic field, the magnetically
retained CD3+ cells could be eluted as the positive cells. Additionally the eluted
CD3+ cells were stained with CD4, CD8, CD3 and sorted by Facs. The remaining
fraction with the cells without CD3+ was stained with CD34FITC, 33PE and 117 PC5
dyes, and the cell fraction CD33, CD34 and CD117 were isolated.
2.10 DNA-techniques
2.10.1 DNA isolation, using QIAamp DNA Blood Midi Kit (Qiagen)
The cell suspension (1x107) was centrifuged and  the pellet was mixed with 180 µl of
Buffer ATL. 20 µl Proteinase K, were added and mixed by vortexing followed by
incubation at 56°C for 10 min. Briefly the 1.5 ml microcentrifuge tube was centrifuged
to remove drops from the inside of the lid. 200 µl Buffer AL were added to the
sample, and mixed by pulse-vortexing for 15 sec., and incubated at 70°C for 10 min.
Briefly the 1.5 ml microcentrifuge tube was centrifuged. 200 µl ethanol (96–100%)
were add to the sample, and mixed for 15 sec. After mixing, briefly the 1.5 ml
microcentrifuge tube was centrifuged. The mixture was transferred to the QIAamp
spin column (in a 2 ml collection tube) and centrifuged at 6000 x g (8000 rpm) for 1
min. The QIAamp spin column was place in a clean 2 ml collection tube. 500 µl
Buffer AW1 was added followed by centrifugation at 6000 x g (8000 rpm) for 1 min.
The QIAamp spin column was placed in a clean 2 ml collection tube. 500 µl Buffer
AW2 was added and centrifuged at full speed (20,000 x g; 14,000 rpm) for 3 min.
The QIAamp spin column was placed in a clean 1,5 ml collection tube and 30-50 µl
prewarmed TE buffer was pipetted directly to the QIAamp spin column followed by
centrifugation at 8000 xg for 1 min.
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2.10.2 Whole genome preamplification
2.10.2.1 REPLI-g Kit (Qiagen)
Solution A: 0.4 ml 5M KOH; 0,1 ml 0,5M EDTA pH 8.0 and 5,5 ml H2O
Denaturation solution: 5 µl solution A and 35 µl H2O
Neutralisation Solution: 3 µl solution B(Kit) and 27 µl H2O
2.5 µl Denat. solution was added to 2,5 µl DNA (5-10 ng) and incubated for 3 min at
RT. The reaction was stopped with 5 µl Neutral solution. Next, a mix – 27 µl H2O;
12,5 µl 4xMix; 2,75 µl DNA-polymerase - was added to each reaction and incubated
at 300C for 16h and at 650C for 3 min.
2.10.2.3 GenomiPhi DNA Amplification (Amersham)
To be amplified 1 µl of a template (5-10 ng) is added to 9 µl of sample buffer and is
heated to 950C for 3 min to denature the template DNA. The sample is cooled and
mixed with 9 µl of reaction buffer and 1 µl of enzyme mix, and incubated at 300C
overnight (16-18h). After amplification, Phi29 DNA polymerase is heat-inactivated
during a 10 min incubation at 650C
2.10.3 PCR assays for monitoring of chimerism by STR analyses
STR analysis refers to 'short tandem repeat.' This type of DNA analysis works to
examine individual areas in DNA. The differences for certain DNA regions in one
person versus another can allow for distinguishing between individuals. Despite the
fact that humans share the overwhelming majority of the same DNA, the tiny fraction
of a percent that varies can be exploited to create a profile of the individual.
The method is based on amplification with one reaction of twelve highly polymorphic
autosomal loci and the sex specific Amelogenin- Locus. One of the two
corresponding primers is labelled with fluorescence dye: 6-FAM, Hex or NED.
The recommended amount of DNA is 0.2-2.0 ng. Additionally: 5 µl Reactionmix D
(kit); 2.5 µl Primermix (kit); 0.4 µl TaqDNA Polymerase (hot start, 2.5 U/µl) and to
25µl volum Nuclease free water were added.
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The following cycling conditions were generally used:
Initial denaturation                                         95°C, 4 min
35 cycles              Denaturation               95°C, 30 sec
                             Annealing                   60°C, 120 sec
                             Elongation                  72°C, 30 sec
Final elongation                                       68°C, 60 min
The electrophorese was done using ABI PRISM 3130XL Genetic Analyzer (Applied
Biosystems, Darmstadt, Germany), or ABI 377.
2.10.4 Amplification of DNA by PCR
Polymerase Chain Reaction (PCR) is a general method to amplify in vitro a specific
nucleotide sequence from a matrix molecule, called template. In this work, PCR
amplification was used to obtain specific DNA fragments from human. Generally
AmpliTaq gold DNA polymerase was used (see 2.2.2).
Components of a typical PCR reaction were as follows:
- DNA template (5-30 ng)
- downstream and upstream primers (both 30 pmol)
- dNTPs mix (dATP, dCTP, dGTP and dTTP in the final concentration of 800 µM) -
- 10 x reaction buffer with MgCl2 (in the final concentration of 1x)
- 2 U of the DNA polymerase
The following cycling conditions were generally used:
Initial denaturation                                                95 °C, 11 min
30-35 cycles                          Denaturation           94 °C, 30 sec
                                              Annealing                Tm - 6 °C, 30 sec – 2 min
                                             Elongation                72 °C, 30sec
Final elongation                                                    60 °C, 45 min
Melting temperature of the primers was determined from the following equation:
Tm = 63.9 + 0.42 (G + C) – 650/n, where Tm is a melting temperature, in ºC, (G + C)
– a GC content of the primer, and n – a primer length. The composition of reaction
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mix and cycling conditions were slightly modified depending on the expected product
length as well as enzyme and template used. PCR products were then purified by
means of QIAquick PCR Purification kit (see 2.2.3) in accordance with manufacture’s
instructions and if necessary sequenced as described below (see 2.10.11).
2.10.5 Agarose gel electrophoresis
Solutions:
50 x TAE buffer :              242 g Tris base
                                         57.1 ml glacial acetic acid
                                        100 ml 0.5 M EDTA (pH 8.0)
EB-stock solution:            10 mg/ml
6 x gel-loading buffer:      10 mM Tris-HCl (pH 7.6)
                                         60 % (v/v) glycerol
                                         60 mM EDTA (pH 8.0)
                                         0.03 % bromphenol blue
For visualisation and separation of DNA fragments, a standard horizontal agarose gel
electrophoresis was used. The electrophoresis was performed in 1 x TAE buffer at 8-
10 V/cm at room temperature. Gel percentage was determined according to the size
range of the DNA fragments and was typically 1.5-3% (w/v) of agarose. Ethidium
bromide was added to gels to the final concentration of 0.4 µg/ml. The DNA samples
were mixed with 1/4 volume of 6 x gel-loading buffer and loaded into the sample
wells. After electrophoresis, the EB-DNA complexes were visualized directly under
UV light.
2.10.6 Cloning of DNA fragments
Fresh PCR product (0.5 to 4 µl) was mixed with upto 5 µl water and 1 µl Topo vector
to a final volume of 6 µl and incubated for 5 min at room temperature. The TOPO®
Cloning reaction could be stored at -20°C overnight or immediately used for to the
transformation of competent cells
2.10.7 Transformation of competent E. coli
The cells were thawed on ice and 100µl of the cells were transferred to a 2 ml
collection tube. After that 1-50ng DNA (0.1-5 µl) was added. The mix was incubated
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on ice for 30min and then for 30 sec in a 42°C water bath. The vial(s) was placed on
ice for 2 min. After the addition of 900 µl of S.O.C medium to each vial, (sterile
techniques must be practised to avoid contamination) the tubes were incubated at
370C for one hour at 225 rpm in a shaking incubator.  After incubation 150 µl of the
cells were spread on a LB plate with appropriate antibiotics and the plates were
incubated at 37°C overnight. The remaining transformation mix could be stored at
+4°C and plated out the next day, if desired. Selected colonies were analysed by
plasmid isolation, PCR, or sequencing.
2.10.8 Mini-preparation
(QIAprep Spin Miniprep Kit Protocol)
This protocol was designed for purification of up to 20µl of high-copy plasmid DNA
from 2-5 ml overnight cultures of E. coli in LB (Luria-Bretani) medium. Pelleted
bacterial cells were resuspended in 250µl of Buffer P1 and transferred to a microfuge
tube. 250 µl of Buffer P2 was added. 350 µl of Buffer N3 was added and tubes were
centrifuged for 10 min. The supernatants were applied to the QIAprep column by
pipetting and centrifuged for 30 sec. QIAprep spin column was washed by adding
0.75 ml of Buffer PE and centrifuged for 30 sec and then for an additional 1 min to
remove residual wash buffer. Further QIAprep spin column was placed in a clean
1.5-ml microfuge tube. To elute DNA, 50µl of dH20 was added and centrifuged for 1
min. EB (10mM Tris-Cl, pH 8.5)
2.10.9 Maxi-preparation
(using the HiSpeed® Plasmid Purification Handbook)
A single colony was picked from a freshly streaked selective plate and incubated first
in 2-5 ml LB medium containing the appropriate selective antibiotic for 8 hours at
370C at 225 rpm in a shaking incubator and then in 250 ml for an additional 12-16
hours at 370C with vigorous shaking (225rpm). After that the bacterial cells were
harvested by centrifugation at 6000xg for 15 min at 4°C and resuspended in 10 ml
Buffer P1. Then 10 ml Buffer P2 was added and incubated at room temperature for 5
min. After that 10 ml of chilled Buffer P3 was added to the lysate and the whole mix
was poured into the barrel of the QIAfilter Maxi Cartridge and filtrated into the
HiSpeed Maxi Tip after the equalibrated by applying 10 ml Buffer QBT. The HiSpeed
Maxi Tip was washed with 60 ml QC buffer and the DNA elution was performed with
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15 ml Buffer QF. The DNA was precipitated by adding 10.5 ml room-temperature
isopropanol and bound to QIAGEN membrane. DNA was washed with room-
temperature 70% ethanol and eluted with 1ml dH20.
2.10.10 Digestion of DNA with restriction endonucleases
Restriction enzyme digestions were generally performed by incubating of DNA
molecules with an appropriate amount of a restriction enzyme under proper
conditions. For analytical digestion, 500 ng of DNA were mixed with 2 U of enzyme
and a corresponding buffer in a volume of 20 µl and incubated at 37 ºC for 2 h.
Digestion of plasmid DNA (40 µg) was carried out in a volume of 40-60 µl overnight
with 40-50U of enzyme. In the case of double digestion with two different
endonucleases, a buffer providing a maximal activity for both enzymes was selected.
2.10.11 DNA sequencing
DNA sequencing was performed by the modified dideoxy-mediated chain termination
method (Sanger et al., 1977). For sequencing reactions, the Big Dye Terminator v
3.1 cycle sequencing kit from Applied Biosystem (Foster City, CA, USA) (see 2.2.3)
was used as described by the manufacturer. 100-200ng DNA were mixed with 7 µl
primer (0,47 µM) and 2 µl Big Dye Terminator v3.1 sequencing buffer. The following
PCR conditions were performed:
35 cycles         95°C, 10 sec
                        55°C, 5 sec
                        60°C, 4 sec
The sample were purified using centrifugation at 730 x g for 2min. through 600 µl
Sephadex G50 (2.4 g diluted in 28.8 ml aqua dest).
Sequencing itself was done with ABI PRISM 3130X Genetic Analyzer Applied
Biosystems, Darmstadt, Germany (see 2.1).
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2.11 HG 10K SNPArrays Hybridization
2.11.1 Buffers
12 X MES Stock
For 1000 mL:
Wash A: Non-Stringent Wash Buffer
For 1000 ml:
♦ MES Hydrate - 70.4 g
♦ MES Sodium Salt - 193.3 g
♦ Molecular Biology Grade water - 800 ml
Mix and adjust volume to 1,000 mL.
The pH should be between 6.5 and 6.7.
Filter through a 0.2 µM filter.
♦ 20X SSPE - 300 ml
♦ 10% Tween-20 – 1.0 ml
♦ water - 699 ml
Filter through a 0.2 µm filter.
Store at room temperature.
Wash B: Stringent Wash Buffer
For 1000 mL:
1X Array Holding Buffer
For 100 mL:
♦ 20X SSPE - 30 ml
♦ 10% Tween-20 – 1.0 ml
♦ water - 969 ml
Filter through a 0.2 µm filter.
Store at room temperature.
♦ 12X MES Stock Buffer - 8.3 ml
♦ 5M NaCl - 18.5 ml
♦ 10% Tween-20 – 0.1 ml
♦ water - 73.1 ml
Store at 2°C to 8°C, and shield from light
Stain Buffer for HG 131 XbaI
For 3 stains:
Stain Buffer for HG 142 XbaI
For 2 stains
♦ SSPE – 450 µl
♦ Tween 20 (3%) – 5 µl
♦ Denhardt´s (50) – 30 µl
♦ H2O - 666.7 µl
♦ SSPE (20X) - 300 µl
♦ Tween-20 (3%) - 3.3 µl
♦ Denhardt’s (50X) – 20 µl
2.11.2 Digestion and ligation procedure
To digest the DNA, follow mix was prepared: NE buffer 2 (10X) 2 µL; BSA (10X (1
mg/mL)) 2 µL and Xba I (20 U/µL) 0.5 µL 250 µg DNA and H2O to 20 µl and
incubated at 37ºC for 120 minutes and at 70ºC for 20 minutes. Than to the digested
DNA was added Adaptor Xba (5 µM) 1.25 µL; T4 DNA Ligase buffer (10X) 2.5 µL
and T4 DNA Ligase 1.25 µL to a total volume of 25 µl and incubated at 16ºC - 120
minutes and at 70ºC - 20 minutes.
2.11.3 PCR reaction
To the ligated DNA (25 µl) was added 75 µL dH2O and afterwards PCR MM was
prepared: PCR buffer (10X) 10 µL; dNTP (2.5 mM each) 10 µL; MgCl2 (25 mM) 10
µL; PCR Primer Xba (10 µM) 7.5 µL; AmpliTaq Gold® (5 U/µL) 2 µL; H2O 50.5 µL.
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To this MM (90 µl) 10 µl from the diluted ligated DNA was added. From each probe 4
PCR reactions were prepared. The following cycle was chosen:
Initial denaturation                                         95°C, 3 min
35 cycles              Denaturation               95°C, 30 sec
                             Annealing                   59°C, 30 sec
                             Elongation                  72°C, 30 sec
Final elongation                                       72°C, 7 min
The reaction was controlled by Gel electrophoresis: 3 µL of each PCR product were
mixed with 3 µL 2X Gel Loading Dye and run on 2% TBE gel at 120V for 1 hour.
2.11.4 PCR Purification Fragmentation and Labelling
The PCR product was cleaned using the MinElute 96 UF PCR Purification Kit
(Qiagen, Hilden, Germany). The cleaning procedure is described in the Mapping 10K
2.0 Assay Manual. The purified DNA was eluted with 40 µl EB buffer.Purified PCR
product (20 µg in EB buffer) 45 µL was mixed with 5 µL 10X Fragmentation Buffer to
a total volume 50 µL. The following MM was prepared: Fragmentation Reagent 3 µL;
10X Fragmentation Buffer 12.5 µL and H2O 109.5 µL. 5 µl from this MM was mixed
with 50 µL Fragmentation Mix and incubated at 37ºC for 30 minutes and at 95ºC for
15 minutes. The fragmentation was controlled by Gel electrophoresis: 4 µL of
fragmented PCR product was mixed with 4 µL gel loading dye and run on 4% TBE
gel at 120V for 30 minutes to 1 hour.
To label the fragmented DNA: 5X TdT Buffer 14 µL; GeneChip DNA Labeling
Reagent (5 mM) 2 µL was added; and TdT (30 U/µL) 3.4 µL and incubated at 37ºC
for 2 hours and at 95ºC for 15 minutes
2.11.5 Hybridization, Wash and Stain procedures
The hybridization wash and stain procedures were performed as described in genetic
Mapping 10K 2.0 Assay Manual. The hybridization mix also contains control
nucleotides. After the hybridization of the Arrays at 48°C for 16 to 18 hours at 60 rpm,
they were stained with Streptavidin phycoerythrin conjugat and finally washed. The
scanning procedure was performed using GeneChip Scanner 3000.
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Fig.2.1 GeneChip Mapping Assay
2.12 RNA-techniques
2.12.1 RNA isolation, using QIAamp RNA Blood Mini Kit (Qiagen)
The cell suspension (1x107) was centrifuged and the pellet was mixed with 200 µl EL
buffer followed by centrifugation for 10 min at 400 xg and 4 °C. 350 µl Buffer RTL
were added and the suspension was mixed by vortex. The mixture was transferred to
the QIAshredder spin column (in a 2 ml collection tube) and centrifuged at maximum
speed for 2 min. The QIAshredder spin column was removed and to the mixture
350µl 70% ethanol were added. The mixture were transferred to the QIAamp spin
column (in a 2 ml collection tube) and centrifuged for 15 sec. at ≥ 8000 xg. The
QIAamp spin column was placed in a clean 2 ml collection tube. 700 µl Buffer RW1
were added followed by centrifugation at 8000 xg for 15 sec. The QIAamp spin
column was placed in a clean 2 ml collection tube. 500 µl Buffer RPE were added
followed by centrifugation at 8000 x g for 15sec. 500 µl RPE Buffer were added again
and centrifuged at max speed for 3min. The QIAamp spin column was placed in a
clean 1,5 ml collection tube and 30-50 µl RNAse free water were pipetted directly to
the QIAamp spin column followed by centrifugation at 8000 x g for 1 min.
2.12.2 Reverse transcription RNA to cDNA and Real Time quantitative PCR
The following mix was prepared: 1.5 µl dNTP (25 µM), 4.0 µl 5xRT Puffer, 1 µl pd(N)6
and added to 1 µg RNA followed by incubation of 650C for 10 min. After the
PCR
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incubation of ice for 10 min. 1 µl RNAse Inhibitor and 1 µl Superskript (Promega)
were added and incubated at 37 0C for 2h followed by incubation of 900C for 10 min.
cDNA is stored at –200C.
The Real Time quantitative PCR reaction was performed using the Power SYBR®
Green PCR Master Mix and Real Time quantitative PCR protocol from Applied
Biosystem. 25 µl Master Mix (kit) and 0.5-3 µl primer were added to 1 µl of the cDNA
and diluted to 50 µl with aqua dest. The following PCR condition were performed:
HOLD                          95 °C, 10 min
40 cycles                     94 °C, 15 sec
                                    60 °C, 1 min
2.12.3 RNA Precipitation
For concentration of RNA samples, a standard procedure of alcohol precipitation was
used. 1/10 volume 3M NaOAc, pH 5.2, and 2.5 volumes 100% ethanol were added to
the RNA sample and incubated at -20°C for at least 1 hour. After centrifugation at ≥
12,000 x g in a microcentrifuge for 20 minutes at 4°C, the RNA pellet was washed
with cold 80 % ethanol solution, followed by air drying and dissolved in DEPC-treated
H2O.
2.13. Gene expression procedure using GeneChip® Human Genome
U133A arrays from Affymetrix
For One-Cycle Eukaryotic Target Labelling Assay experimental outline total RNA (1
µg to 15 µg) is first reverse transcribed using a T7-Oligo(dT) Promoter Primer in the
first-strand cDNA synthesis reaction. Following RNase H-mediated second-strand
cDNA synthesis, the double-stranded cDNA is purified and serves as a template in
the subsequent in vitro transcription (IVT) reaction. The IVT reaction is carried out in
the presence of T7 RNA Polymerase and a biotinylated nucleotide
analog/ribonucleotide mix for complementary RNA (cRNA) amplification and biotin
labelling. The biotinylated cRNA targets are then cleaned up, fragmented, and
hybridized to GeneChip expression arrays.
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2.13.1 Buffers
12 X MES Stock
For 1000 mL:
Wash A: Non-Stringent Wash Buffer
For 1000 ml:
MES Hydrate – 64.61 g
MES Sodium Salt - 193.3 g
Molecular Biology Grade water - 800 ml
Mix and adjust volume to 1,000 mL.
The pH should be between 6.5 and 6.7.
Filter through a 0.2 µM filter.
20X SSPE - 300 ml
10% Tween-20 – 1.0 ml
water - 699 ml
Filter through a 0.2 µm filter.
Store at room temperature.
Wash B: Stringent Wash Buffer
For 1000 mL:
2X Hybridization Buffer
For 50 mL:
12x MES Stok Buffer – 83.3ml
5M NaCl – 5.2ml
20X SSPE - 30 ml
10% Tween-20 – 1.0 ml
water – 910.5 ml
Filter through a 0.2 µm filter.
Store at room temperature.
12X MES Stock Buffer - 8.3 mL
5M NaCl - 17.7 mL
0.5M EDTA - 4.0 mL
10% Tween-20- 0.1 mL
water - 19.9 mL
Store at 2°C to 8°C, and shield from light
2X Stain Buffer
For 250 mL
SAPE –Solution mix
For 2 stains
12X MES Stock Buffer - 41.7 ml
5M NaCl - 92.5 ml
10% Tween-20 - 2.5 ml
water - 113.3 ml
Filter through a 0.2 µm filter
Store at 2°C to 8°C and shield from light
2X Stain Buffer 600.0 µL
50 mg/mL BSA 48.0 µL
1 mg/mL Streptavidin Phycoerythrin 12.0
µL
DI H20 - 540.0 µL
Total Volume 1200 µL
Antibody Solution mix
For 1 stain
2X Stain Buffer 300.0 µL
50 mg/mL BSA 24.0 µL
10 mg/mL Goat IgG Stock 6.0 µL
0.5 mg/mL biotinylated antibody 3.6 µL
DI H20 266.4 µL
Total Volume 600 µL
2.13.2 The first strand synthesis
RNA should be of good quality.
First 5-8 µg RNA was mixed with 2 µl T7-dT24-Primer (50 pmol/µl) and to a final
volume of 20 µl dH2O and incubated at 70
0C for 10 min. 4 µl 5xFirst strand cDNA
buffer, 2 µl 0.1M DTT and 1 µl 10 mM dNTP were added and incubated for 2 min at
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42 0C. Then 1 µl Super Script II RT (200 U/µl) was added and incubated for 1 hour at
42 0C.
2.13.3 Second strand reaction
The following mix was be prepare and added to the first strand reaction:
91 µl Water-DEPC treated, 30 µl 5x 2th Strand Reaction Buffer, 3 µl 10 mM dNTP
mix, 1 µl 10 U/µl E. coli DNA Ligase, 4 µl 10 U/µl E. coli DNA Polymerase I and 1 µl
2U/µl E. coli Rnase H.
The mix was incubated for 2 hours at 16 0C. Than 2 µl 10 U T4 Polymerase was
added followed by incubation for 5 min at 16 0C and the reaction was stopped with
10µl 0.5M EDTA.
2.13.4 Cleanup of double – stranded cDNA
To the double – stranded cDNA was added 600 µl cDNA binding buffer and then this
mixture was applied to the spin column and centrifuged for 1 min at 8000 xg. The
spin column was washed with 750 µl cDNA wash buffer and centrifuged 1 min at
8000xg. The spin column was dried for 5 min at max speed and the cDNA was eluted
with 14 µl cDNA Elution buffer.
2.13.5 Synthesis of biotin – labelled cDNA
the following Master mix was added to the cleaning cDNA. :
Water                                                           10 µl
10 HY reaction buffer (vial 1)                       4 µl
10x Biotin labelled Ribonucleotides (vial 2)  4 µl
10x DTT (vial 3)                                           4 µl
10x Rnase Inhibitor Mix  (vial 4)                  4 µl
20x T7 RNA Polymerase (vial 5)                 2 µl
12 µl Template cDNA was added and incubated at 370C for 5 hours
2.13.6 Cleanup of biotin – labelled cRNA
60 µl Rnase – free water were added to the cRNA, 350 µl IVT cRNA binding Buffer
and 250 µl ethanol (100%). The samples was applied to the IVT cRNA Cleanup Spin
Column, and was centrifuged for 15 sec at 8000 xg. The Spin Column was washed
with cRNA Wash Buffer (15 sec at 8000 xg). 500 µl 80% ethanol was added,
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centrifuged by 8000 xg and the membrane was dried for 5 min at max speed. The
cRNA was eluted with 30 µl RNAse free water.
2.13.7 Quantification from the IVT Product
Adjusted cRNA yield = RNAm – (total RNAi) (y)
RNAm = amount of cRNA measured after IVT (µg)
Y = Fraction of cDNA reaction used in ITV
2.13.8 Fragmenting the cRNA for Target Preparation
The following mix: 20 µg cDNA, 8 µl 5x Fragmentation Buffer and water to 40 µl was
incubated for 35 min at 940C.
2.13.9 Hybridization, Wash and Stain procedures
The hybridization, wash and stain procedures were performed as described in
GeneChip® Expression Analysis Technical Manual. The hybridization mix also
contains different control oligonucleotides. After the hybridized of the Arrays at 450C
for 16 hours at 60 rpm, they were stained with Streptavidin phycoerythrin conjugate
and finally washed. The scanning procedure was performed using GeneChip
Scanner 3000.
2.14 Cell culture methods
2.14.1 Cell culture techniques
The mammalian cells, which were used in this work, were grown in suspension in
plastic flasks. The plastic was obtained in sterile wraps from commercial suppliers
and is specially prepared for use in cell culture. All these tissue culture flasks have
caps with filters which permit gaseous exchange, allowing maintenance of correct pH
(which is monitored by the colour of the phenol red present in the medium) and the
right percentage of CO2 (5%). The optimal atmosphere conditions are maintained by
a CO2 incubator, which automatically controls temperature and pCO2. The incubator
temperatures are set at 37°C and regularly checked. The relative humidity was ~
95%. The use of plastic pipettes and special medium (very low endotoxin) was
necessary to work in endotoxin-free conditions. The cell lines used in this project
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were acquired from DSMZ - the German Collection of Microorganisms and Cell
Cultures (Braunschweg, Germany). The cells were seeded every 3 days in fresh
medium with 1x106 cell/ml density. When necessary zeocin in a concentration of
4mg/ml was added.
2.14.2 Cell quantification and evaluation of viability
An efficient way of counting cells and at same time evaluating the percentage of
viable cells is the technique of “dye exclusion”. This test is based on the concept that
viable cells do not absorb some dyes, whereas dead cells are permeable to these
dyes. Trypan blue is the most commonly used dye, but has the disadvantage of
staining soluble proteins. In the cell culture however some situations such as recent
trypsinization and freezing and thawing in the presence of dymethylsulphoxide
(DMSO) may lead to membrane leakness. From each suspension cell an aliquot of
10 µl was harvested, mixed with 10 µl of Tryplan Blue (ratio cells:trypan blue=1:1)
and counted on a counting slide under the microscope. The mean of at least three
counts of viable cells (not stained with trypan blue) pro quadrant was calculated and
multiplied to the magnitude (104) and the dilution factor.
Cell quantification was also done using XE –2100 Sorter (Sysmex). The Cells in
RPMI medium were measured directly.
2.14.3 Storage of cells
In order to minimise the cellular injury induced by freezing and thawing procedures
(intracellular ice crystals and osmotic effects), a cryoprotective agents such as
dimethyl sulphoxide (DMSO) were added. A variable number of suspension cells
between 2-10 x 106 were spun down and resuspended in a 500 µl freezing medium
(10% DMSO, 20% fetal calf serum amd 20% RPMI medium).
The cell culture freezing medium was thawed and mixed well by a gently swirling
bottle. The medium could be kept on ice during use. Before to be frozen the cells
should be in late log phase growth. While short-term preservation of cell lines using
mechanical freezers (-80°C) is possible, storage in liquid nitrogen (-196°C) or its
vapour (-120°C) is much preferred. Rapid thawing of cell suspension is essential for
optimal recovery.
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2.14.4 Determining of Cell Drug Sensitivity
In this project pmHPRT-DRGFP vector with selective drug puromycin was used. It
was necessary to determine for each cell line what level of drug selection will kill
nonresistant cells. 500 000 cell/ml were seeded in a fresh medium and puromycin
with a final concentration of 0, 0.5, 1, 1.7, 2.8, 3.5 µg/ml was added. The cells were
incubated at 370C in a humidified incubator with 5% CO2 for 5 days. The minimal
concentration of puromycin that was necessary to kill all the cells was applied Table
2.5.
Table 2.5 The minimal concentration of puromycin needed to kill all nonresistent cells.
Cell lines Puromycin
µg/ml
MV4-11 1.7
Molm13 1.7
K562 2.8
THP1 2.8
2.14.5 Transfection of the cells
2-4x107 Cells in the log phase were washed and resuspended in 300 µl of PBS or
RPMI without phenol red. 40 µg of the plasmid DNA were added and mixed by
pipetting up and down. Than the cell suspension was added to a 0.4 sm.
electroporation cuvet and incubated for 10 min on ice. The DNA/cell suspension was
electroporated with appropriate voltage and capacitance. The mixture was left for 10-
15 min at room temperature and then resuspended in 10 ml RPMI medium (1% P/S
and 10% FCS) prewarmed to 370C.
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2.15 Chemiluminescence Detection of H2A.X Phosphorylation
2.15.1 Buffers:
1X TBS:
50ml 20X TBS with 950ml sterile water were mixed to create a
working solution of 1X TBS. Store at room temperature.
1X TBS/T (Wash Buffer):
1.5ml 20% Tween®-20 (v/v) was deluded in 600ml 1X TBS to create a working
solution of 1XTBS with 0.05% Tween®-20 (v/v). Store at room temperature.
Blocking Buffer:
12 ml 10% BSA were diluted in 28 ml of 1X TBS to make a working solution of 3%
BSA in TBS. This solution is stable for several days at 4°C.
1% Formaldehyde in TBS:
405.5µl 37% formaldehyde solution (formalin) was diluted in 15ml 1X TBS. This
solution must be prepared fresh.
95% EtOH/5% Acetic Acid:
750µl acetic acid was diluted in 14.25ml of ethanol. This solution must be prepared
fresh.
Primary Antibody Solution:
75µl anti-phospho histone H2A.X was diluted in 10ml Blocking Buffer. Store at 4°C.
Detection Antibody Solution:
10µl Goat Anti-Mouse HRP was diluted in 10ml Blocking Buffer. Store at 4°C.
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2.15.2 Fixing Cells to 96-Well Cell Culture Plates
The media from the wells was aspirated and approximately 10µl of media were left.
125µl/well of 95% EtOH 5% acetic acid fixing agent was added Immediately and
incubated for 7 minutes at room temperature. The fixing agent from the wells was
removed and the plate was tapped gently onto absorbent paper to remove any
excess fixing agent still within the wells. 150µl/well of 1% formaldehyde in TBS was
added and incubated for 5 minutes at room temperature. Formaldehyde solution from
the wells was removed and the plate was tapped gently onto absorbent paper to
remove any excess liquid. 150µl/well Wash Buffer (1X TBS/T) was added and
incubated for 1 minute at room temperature. The wash buffer was removed and the
plate was once again tapped gently onto absorbent paper. 150µl/well Blocking Agent
(3% BSA in TBS) was added and incubated for 1 hour at 37°C or overnight at 4°C.
2.15.3 Addition of Primary and Secondary Antibodies
The blocking agent was removed and the wells were rinsed once with 300µl/well of
Wash Buffer. The Wash Buffer was removed and the plate was tapped gently onto
absorbent paper. 100 µl/well of Primary Antibody Solution was added and incubated
for 1 hour at 37°C. After the incubation the Primary Antibody were removed and the
wells were rinsed once with 300 µl/well of Wash Buffer. After that the Wash Buffer
was removed and the plate was taped gently onto absorbent paper. The cells were
washed 3-5 times with 150 µl/well Wash Buffer for ~3 minutes each with gentle
agitation. 100 µl/well of the Detection Antibody were added and incubated for 1 hour
at room temperature.
2.15.4 Luminescence Detection
The Detection Antibody was removed and the wells were  rinsed once with 300µl/well
Wash Buffer. The wells were washed 3-5 times with 150µl/well Wash Buffer for ~3
minutes. During the last wash, LumiGLO™ substrate was prepared. For each plate,
8ml of 1:1 (v/v) mixture of LumiGLO™ Chemiluminescent Substrate Reagent A and
LumiGLO™ Chemiluminescent Substrate Reagent B were prepared. After the last
wash with Wash Buffer, the wells were rinsed once with 300µl/well 1X TBS and the
plate was taped gently onto absorbent paper.
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75µl/well of prepared LumiGLO™ substrate was added. The plate was read on 96-
well microplate luminometer between 10 and 20 minutes after the addition of
LumiGLO™ substrate.
2.16 Immunofluorescence staining of suspension cells
Indirect immunofluorescence staining is used to visualise the subcellular distribution
of biomolecules of interest. In this project combination of one antibody with a
chemical fluorescence dye (DAPI for nuclei) and protein specific monoclonal antibody
from a mouse was used (see 2.2.4). Subsequently, an antimouse secondary, dye-
coupled (Cy3) antibody was introduced that recognised the primary antibody.
Briefly, the cells were fixed with 4% PFA for 20 min. at room temperature (RT). and
washed. The cells were incubated for 10 min at RT and washed again twice with
PBS. The permeabilisation of the cells was done with 0.2% Triton for 5 min at RT
followed by blocking with 10%FCS in PBS for 1h at RT. The cells were washed again
twice with PBS. 20 µl of the primary antibody in Blocking buffer (1:50) was added and
incubated for 1h at RT and washed with PBS. 20 µl of the fluorescently labelled
secondary antibody in blocking buffer (1:100) was added and incubated for 30 min. at
RT follow by PBS wash. Additionally the nuclei were visualised with DAPI. For the
visualisation of the stained biomolecule.
2.17 Statistical methods
2.17.1 Chi-square test
A chi-square test is any statistical hypothesis test in which the sampling distribution
of the test statistic is a chi-square distribution when the null hypothesis is true, or any
in which this is asymptotically true, meaning that the sampling distribution (if the null
hypothesis is true) can be made to approximate a chi-square distribution as closely
as desired by making the sample size large enough.
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2.17.2 logrank test
The logrank test is a hypothesis test to compare the survival distributions of two
samples. It is a nonparametric test and appropriate to use when the data are right
censored (technically, the censoring must be non-informative). It is widely used in
clinical trials to establish the efficacy of new drugs compared to a control group when
the measurement is the time to event.
2.17.3 Kaplan–Meier estimator
The Kaplan–Meier estimator estimates the survival function from life-time data. In
medical research, it is used to measure the fraction of patients living for a certain
amount of time after treatment.
A plot of the Kaplan–Meier estimate of the survival function is a series of horizontal
steps of declining magnitude which, when a large enough sample is taken,
approaches the true survival function for that population. The value of the survival
function between successive distinct sampled observations ("clicks") is assumed to
be constant.
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3. Results
3.1 Detection of loss of haetherozygosity (LOH) in AML patients
with normal karyotype using GeneChip Mapping 10K Array
Chromosome abnormalities are associated with a wide range of clinical problems
including cancer. The identification and characterisation of chromosome
abnormalities represent the basis of cytogenetic analysis and are crucial for accurate
diagnosis and prognosis. Current methods used for assessing chromosomal integrity
and copy number focus on microscopy of metaphase chromosome spreads and
interphase nuclear preparation. These techniques include karyotyping and
fluorescence in situ hybridization (FISH). Despite the great diagnostic and prognostic
benefits provided by these methods, they have some disadvantages such as limited
resolution. Furthermore they are not well suited for identifying regions of the genome
that have undergone LOH (Loss of Hetherozygosity) as in the case of a single allele
present without a reduction in copy number. With the completion of the human
genome, single nucleotide polymorphisms (SNPs), the most common sequence
variation among individuals, are emerging as the marker of choice in large-scale
genetic studies due to their abundance, stability and relative ease of scoring. These
characteristics make SNPs powerful markers for LOH studies. High-density DNA
array technology has been applied to Affymetrix for the identification of genomic
alterations in tumour cells, most notably LOH. Recently a method termed “whole
genome sampling analysis” was developed for large-scale SNP genotyping of
complex DNA. The SNPs on the GeneChip Mapping 10K Array were selected from
Affymetrix through a stringent and iterative process which utilised genotype clustering
patterns, genotype calls, accuracy, reproducibility, heterozygosity, and genome
coverage as the selection criteria. Extensive testing and validation of 11,555 SNPs
on the Mapping 10K Array demonstrated that they consistently generate correct call
rates and are reliable and informative across several ethnic populations. The physical
and genetic maps show that coverage of the SNPs on the Mapping 10K Array is
comprehensive, with a median physical distance between SNPs of approximately
105 kb and an average distance of 210 kb. The median genetic distance between
SNPs is approximately 0.10 cM (genetic distance) and the average distance is
approximately 0.31 cM. This ensures the sufficient coverage and significant statistical
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power of the Mapping Array making this method ideally suited for linkage analysis
and other genetic research (Fig.3.1).
Fig.3.1 Distribution of SNPs across the genome.
Red vertical bars represent the presence of at least one SNP in 100-kb regions. Black
vertical bars represent large counting gaps that are 100,000 nucleotides or longer.
In this study bone marrow or blood samples from 146 adult patients with newly
diagnosed and untreated AML were analysed for LOH changes using Affymetrix
SNPs Arrays. All patients were diagnosed as having AML according to the standard
French-American-British (FAB) and WHO criteria. The median age in this group was
55 years, 50% were male and 50% female and the patients had different OS after the
induction chemotherapy. The screening was started with the sorting of the blasts
(CD33, CD34 and CD117) and the T-cells (CD3). The T-cells were used as a disease
free control, as a conformation of the somatic nature of SNPs-detected lesions. In the
AML patients, the T-cell count is often very low so the amount of the isolated DNA in
some samples was minor. In these cases whole genome preamplification was
performed using Repli-g kit from Quiagene recommended by Affymetrix. To be sure
that no genetic information was lost, the quality of the DNA after preamplification was
controlled using Humantype Chimera PCR amplification kit (this method is described
Genome Coverage: 10K Arrays10,204 SNPs
Red = at least 1 SNP per 100 kb
Black = Gaps in genome coverage
Median intermarker distance: 113 kb
Mean intermarker distance: 258 kb
Mean genetic gap distance: 0.36 cM
Average Heterozygosity: 0.38
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in the materials and methods section). With this analysis it could be shown that some
loci after preampliffication were lost (data not shown). This loss of genetic information
had a subsequent impact on the technical values after the array hybridization. The
quality of the hybridization was analysed with the GTYPE software from Affymetrix
and is very important to the correct analysis of the copy number changes. Two kinds
of 10K Arrays were used: Macro Array Xba1 131 Assay and Macro Array Xba1 142
Assay. Macro Array Xba1 142 contains fewer SNPs (10,200 SNPs) then Array Xba1
131 (11,555 SNPs) because the SNPs with lower quality were removed. In the Table
3.1 the technical results from some samples are present.
Table 3.1 Technical values after hybridization.
The quality of the hybridization was analysed with GTYPE software. SNP Call and Signal
Detection show the hybridization quality. AA Call AB Call and BB Call show the distribution of
the A and B allele in percent.
However, the technical values of the preamplificated DNA after the hybridization
were lower compared with the values of the primary DNA. To improve the quality of
the preamplificated DNA I compared Repli-g kit with Genomy-Phi kit from Amersham
and confirmed that the loss of the loci with the GenomyPhi was rare (Fig.3.2) and the
quality of the DNA was higher. Thus, with GenomyPhi, it was possible to increase the
technical values after hybridization. In Table 3.2 the differences in the technical data
after hybridization between the primary DNA and the amplificated DNA are shown.
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Fig.3.2 Comparison between Repli-g and Genomy-Phi using Humantype Chimera PCR
Amplification kit.
This method is based on the amplification of 12 high-polymorphic loci. One of the primers is
labelled with fluorescence dye. Of the x-axes are displayed: A) 6 loci - 6-FAM labelled; B) 4
loci - Hex labelled; C) 3 loci - NED labelled. DNA was isolated from 100000 cells (human
control DNA), and for the whole genome preamplification 10 ng were used. After the
amplification with Repli-g kit I found that some loci were lost (shown on the graph with the
red arrows). I could improve the quality of the DNA using Genomy-Phi kit from Amersham so
the missing loci could be detected (shown on the graph with the blue arrows).
Repli-g
Repli-g
Repli-g
Genomy-Phi
Genomy-Phi
Genomy-Phi
A)
C)
B)
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Table 3.2 Mean value of the technical values after the hybridization.
The mean values of SNP Call and Signal Detection were calculated after the hybridisation of
primary DNA and after the hybridization of amplificated DNA with Repli-g and Genomy-Phi
kits.
DNA Preparation SNP Call % Signal Detection %
Primer 96,1 99,1
Repli-g Kit (Quiagen) 78,8 91,1
GenomyPhi Kit (Amersham) 92,8 98,1
3.2 Analyses of copy number changes in AML patients with normal
karyotype
3.2.1 Copy number tool analyses
The copy number changes were analysed with the chromosome copy number
analysis tool 4.0 (CNAT), which provides a graphical interface to facilitate
identification of amplifications, deletions and UPD regions by chromosome for many
sample types. Copy number changes and p-values were calculated based on SNP
hybridization signal intensity data from the experimental sample relative to intensity
distributions derived from a reference set containing over 100 ethnically diverse
individuals (Huang et al. 2004). One typical case with LOH in chr. 11 is illustrated in
Fig.3.3. In the upper panel, four graphs are displayed, showing from top to bottom:
copy number estimation, p-value (or significance), Log2Ratio and LOH probability.
The visible range of the y-axis for each graph is independently user adjustable. The
physical coordinates on the chromosome are displayed along the bottom of the
graphs. In the lower panel, a tabular view of the data along with the genotype calls
and SNP ID, chromosome, and physical positions of each SNP are displayed.
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Fig.3.3 Copy Number Tools analyses in one case with LOH in chromosome 11q.
In the graph:
SPA_CN - Single point analysis of the copy number estimate.
SPA_pVal - Single point analysis of the copy number variation significance. When the value
from the target cell line is higher than the reference mean, –log10(p-value) is used , which is
a positive value, to represent the significance. When the value from the target cell line is
lower than the reference mean, log10(p-value) is used, which is a negative value, to
represent the significance.
CPA_pVal - Continuous point analysis of the significance value (meta analysis significance).
CPA or meta analysis average the significance values over consecutive SNPs which display
the same type of alteration (gain or loss). The higher the possibility values, the greater the
chance the change is real. The average region is defined by a genomic region with a copy
number above or below 2. When the value from the target cell lines is higher than the
reference mean, -log10(p-value) is used, which is a positive value, to represent the
significance. When the value from the target cell line is lower than the reference mean,
log10(p-value) is used, which is a negative value, to represent the significance.
Log2Ratio - Smoothed Log2 ratio value.
LOH - the –log of the probability of continuous genomic region of homozygote calls.
In the LOH-graph, the value is higher than 20 of a large region which is an indication of LOH
possibility.
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In the first 15 patients, both the blasts and the T-cells were analysed for CNT-
changes. The profiles of the blast and the T-cells in two patients with LOH in the
second and in the thirteenth chromosome in Fig.3.4 are shown. In the LOH graph the
ratio of the T-cells is lower than 5, but the ratio of the blasts in some regions is higher
than 25, which is an indication of the LOH probability. In the remaining group of
patients, only the blasts were analysed. In the cases with possible LOH regions the
T- cells were also sorted and hybridized to the SNPs arrays to confirm the changes
found in the blasts.
Fig.3.4 CNT analyses in two patients with UPD.
A. The profile from the T-cells and the blasts from one patient with LOH in chromosome 2p.
In the T-cells, the value is lower than four. In the blasts of a large region, the value is
higher than 20, which is an indication of potential LOH.
B. The profile from the T-cells and the blasts from one patient with LOH in chromosome 13.
The value in the T-cells is lower than six but in the blasts the value in almost the whole
chromosome is higher than 20. This is an indication of Copy Number changes in the
whole chromosome.
A. Chromosome 2
B. Cromosome 13
T-cells Blasts
T-cells Blasts
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Very interesting was the detection of six cases with LOH in the blasts but I also found
this phenomenon in the T-cells with unknown impact of the AML development
(Fig.3.5).
Fig.3.5 CNT analyses in two patients with LOH in the blasts and in the T-cells.
A. T-cells and blasts in one case with LOH in chromosome 20.
B. T-cells and blasts in one case with LOH in chromosome 1.
Using Copy Number Analysis I could also identify some chromosome deletions or
whole chromosome losses in patients classified with normal karyotype according to
current methods. This was possible after the analyses of CAP_pVal value. (see
explanation above (Fig.3.3)). I found two patients with loss of whole chromosome 7
and one patient with deletion in chromosome 10p (Fig.3.6).
T-cells Blasts
T-cells Blasts
A Chromosome 20
B Chromosome 1
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Fig.3.6 CNT analyses in two patients with loss of genetic information.
After the analysis of CPA_pVal I was able to find deletion in chromosome 10p in one patient
and loss of the whole chromosome 7 in two patients.
A. One of the two cases with loss of whole chromosome 7.
B. One case with deletion  in chromosome 10p.
In this way all 146 patients were analysed and LOH in 30 cases was found. As
described above, in 6 patients I confirmed this phenomenon in the blast as well as in
the T-cells. Additionally I detected chromosome losses in 3 patients. I excluded these
9 cases from the UPD group so at the end I could confirm the UPD in 21 cases. The
UPD-regions are located in different chromosomes where in almost all cases the
telomere is also involved and covered between 11.5 and 88 Mb (Fig.3.7). Most
commonly I found this aberration in the 2, 6, 7, 11, 13, and 21 chromosomes.
Remarkably, in two patients, two chromosomes were affected at the same time: in
the first case chromosome 21q and whole chromosome 7 and in the second case
chromosomes 11p and 6p. In Table 3.3, the physical position of the LOH regions in
each chromosome are presented.
 B. Chromosome 10
 Blasts Blasts
 A. Chromosome 7
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Fig.3.7 UPD regions found in 21 patients.
In two patients, two chromosomes with UPD were found: in the first case chr. 21q and 7; in
the second case – 11p and 6p.
Table 3.3 Physical Positions of the UPD regions found from 146 patients in 21 cases.
Physical PositionCase
number
Affected
chromosome
start end
1 LOH 2p 12078062 23603924
2 LOH 11q 111426718 134432350
3 LOH 2p 118345 98040934
4 LOH 11q 62639226 110235093
5 LOH 8q 108910464 122096140
6 LOH 13q 28927722 114040116
7 LOH 22 15685581 48881270
8 LOH 21 13520510 46782195
9 LOH 13 28927722 114040116
10 LOH 6p 150610 33112365
11 LOH 21q 26120971 46782195
LOH 7 7264758 158466134
12 LOH 19q 35572679 63437743
13 LOH 11q 95822028 113791114
14 LOH 11p 2573106 45687359
LOH 6p 150610 34589070
15 LOH 1p 3122295 54241547
16 LOH 11p 2573106 50096862
17 LOH 6p 150610 33112365
18 LOH 3q 103238428 199368514
19 LOH 7q 57299439 96038702
20 LOH 11q 96359849 116705080
21 LOH 11p 2573106 56371866
UPD region
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3.2.2 Short tandem repeat (STR) analyses
To confirm these results, a second method was used - Short tandem repeat analysis
(STR). The method is based on the probability of different fragment lengths between
heterozygosity alleles. Using the Mammalian Genotyping Service database I chose
some STRs from the UPD regions with very high heterozygosity coefficient and
analysed them for allele losses. In Fig.3.8 one example of LOH on chromosome 2 is
presented. I analysed two STRs from Chromosome 2 in the T-cells and in the blasts.
I found that in the blasts one allele was lost compared to the T-cells. In this way I
confirmed the UPD in all 21 cases.
Fig.3.8 STR analyses in one case with UPD in chromosome 2.
In the UPD region, two STRs (D2S139 and D2S285) were analysed for loss of
heterozygosity. In both of them one of the loci in the blasts is missing compared to the T-
cells.
3.3 Relationship between UPD and AML
The next important question addressed was if there is any relationship between the
UPD regions and AML. Currently, some genes in which mutations are directly
connected with the development of AML have been described. So, I decided to look
for the gene mutations important for the AML development in the different UPD
region. For example, one of the most important haematopoietic transcription factors,
T-cells
Blasts
D2S285D2S139
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RUNX1 (runt-related transcription factor 1), located on the chromosome 21
(21q22.3), is often mutated in AML patients. In this study there were two cases with
UPD on the 21q chromosome. Since aberrations in exons 3; 4; 5 from the RUNX1
gene were most often described, I sequenced these regions in both cases. I found
point mutation in each case – in exon 3 and 4 (Fig.3.9). Moreover, the mutations of
the WT1 (Wilms tumor) gene on chromosome 11p were reported to be relevant of the
development of the AML. After sequencing of the exons 1, 6, 7, 8 and 9 from three
patients with UPD in the chromosome 11p, I found a point mutation in the exon 7 in
one of them (Fig.3.10). Additionally, one mutation was found in the CEBPA
(CCAAT/enhancer binding protein) gene in one patient with UPD on chromosome 19
(sequenced by Marika Karger in our lab, data not shown). In this way it was possible
to confirm the relationship between the UPD regions and AML.
Fig.3.9 Mutations in RUNX1 gene in two cases with UPD in chromosome 21q.
The exons 3, 4 and 5 on chr. 21q were sequenced in two patients with UPD. At first, the cells
were sorted and then the blasts were compared with the T-cells (negative control).
A. Point mutation in exon 3 in one of the patients.
B. Insertion in exon 4 in the second case.
A. Exon 3 B. Exon 4
T-cells
Blasts
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3.4 Statistical analyses
Some statistical analyses were performed to discover if UPD has an impact on
Overall Survival (OS), as well as if gender or AML subtype are related to this
aberration. Kaplan-Meier method was used and the analyses were done together
with Fr. Silke Soucek. I could not find any connection between age, WBC-counts
(White Blood Cell counts) or sex and the UPD, but there was a clear correlation
between the UPD and the AML subtype. The FAB M1 subtype was observed in
47.6% of the UPD positive patients, compared to only 19.2% of the UPD negative
patients (P=0.04, n=146). Also I couldn’t find any correlation between FLT3-ITD,
MLL-PTD and NPM1 mutations in the UPD patients. They were present at the same
rate in the UPD cases.
The rate of complete remission (CR) induction was 85.7% in the UPD positive cases
and 76.8% in the UPD negative cases. Of the UPD positive patients in complete
remission after induction chemotherapy, 60.0% relapsed within the first 6 months. In
contrast, the rate of relapse in patients without UPD was only 38.2%, but these
results were not significant (P=0.065).
Fig.3.10 Point mutation in WT1 gene in
one case of the UPD in chromosome
11p.
From 21 UPD positive patients, three
cases with UPD in chromosome 11p were
found. From these patients the cells were
sorted and the blasts were compared with
the T-cells (negative control). After
sequencing of the WT1 gene (exons 1, 6,
7, 8 and 9) in these cases a point mutation
in exon 7 was found in one of them.
T-cells
Blasts
Results 66
Fig.3.11 shows the comparison of the OS between UPD positive patients UPD
negative patients. Only the patients younger than 60 were analysed to exclude the
impact of age on the results. After the induction chemotherapy the UPD positive
patients showed clearly lower OS compared to the UPD negative cases.
Fig.3.11 Kaplan-Meier analysis of the probability of OS in 121 patients with and
without UPD.
Kaplan-Meier analysis of OS in AML patients with normal karyotype younger than 60 was
done. UPD negative patients had a significantly higher probability of OS than UPD positive
cases.
Furthermore, the patients with UPD on chr. 11 had the poorest outcome with a
median OS of 13 months compared to the patients with UPD located on other
chromosomes and UPD negative cases. In Fig.3.12, the patients with UPD on chr. 11
are presented separately from the remaining group of patients with UPD. All 146
patients were analysed.
        UPD negative
        UPD positive
103 UPD negative
18 UPD positive
P=0.05
Months
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Fig.3.12 Kaplan-Meier analysis of the probability of OS in 146 patients with and
without UPD.
The patients with UPD on chromosome 11 are presented separately. They show the poorest
outcome compared to the remaining UPD positive cases and patients without UPD.
3.5 Gene expression analyses using Affymetrix array
Genome-wide gene expression profiling based on DNA microarrays represents one
of the most powerful tools in the area of the current genomics. The utility and promise
of the experimental use of DNA microarray technology to study human cancer has
been demonstrated first by analysing acute leukaemia samples, which included
cases of AML. Although known AML cases were predicted by using supervised data
analysis approaches, new subtypes of AML have been identified with the aid of
unsupervised analytic methodologies. In addition, the feasibility of gene expression-
based outcome prediction in AML has been demonstrated, and DNA microarray
technology has provided novel biological insights by its application to experimental
models. To find out if patients with UPD could be classified in one group based on
the similar gene expression profiling, expression analyses were performed using
GeneChip Human Genome U133A arrays from Affymetrix. I started with five patients
with UPD and compared them to five patients without UPD (the UPD negative cases
        UPD Negative
        UPD Positive (non 11)
        UPD of chr. 11
P=0.03
Months
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were hybridised by Dr. Christine Steudel). After the analysis with Gene Spring
software, I found that the UPD positive patients and the UPD negative patients
segregate into two different gene-expression cluster (Fig.3.13).
Fig.3.13 Gene expression analysis of patients with and without UPD using Gene Spring
software.
Expression analysis were done in 5 UPD positive patients and 5 UPD negative patients using
Affymetrix expression protocol and GeneChip Human Genome U133A arrays. 5µg of high
quality RNA from each patient were used. The UPD positive patients clearly showed a
different gene expression profile compared to the UPD negative patients. 1000 genes were
analysed; P≤0.05.
Blue - low gene expression levels.
Red - high gene expression levels.
I continued this analysis with 14 UPD positive patients compared to 10 UPD negative
cases (the UPD negative cases were hybridised by Dr. Christine Steudel). Also here I
could validate different expression profiling between these two groups. For this
analysis Array Assist software was used. In Fig.3.14 an example of a region with high
gene expression in the patients with UPD compared to the patients without UPD is
presented. Additionally I could identify some genes responsible for the repair process
UPD-positive UPD-negative
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in the human cells that were highly expressed in the UPD positive cases. This first
analysis show that it is possible to separate the UPD positive patients from UPD
negative cases according to the gene expression profile, which could be used for
future research in this field.
Fig.3.14 Gene expression analysis of patients with and without UPD using Array
Assist software.
14 UPD positive patients were compared with 10 UPD negative patients using Affymetrix
expression protocol and GeneChip Human Genome U133A arrays. 5 µg of high quality RNA
were used. It was possible to generate clusters with different expression profiles in the UPD
positive compared to the UPD negative patients. In the graph, one cluster with a high
expression profile in the UPD positive cases is presented. 120 genes were analysed; P≤0.05
Green - low gene expression levels.
Red - high gene expression levels.
3.6 The effect of FLT3-ITD mutation on homologous recombination
3.6.1 Flow cytometry analysis of homologous recombination using the
pmHPRT-DRGFP vector system
Internal tandem duplication (ITD) of the juxtamembrane region of the FLT3 receptor
tyrosine kinase gene is one of the most common aberration in the AML patients. In
this study six of the analysed 21 UPD positive patients, had a FLT3-ITD mutation. A
previous study in our lab showed that the patients with an increased allelic ratio
between mutated and wt FLT3 receptor have a significantly shorter overall and
disease-free survival. The loss of the wt of FLT3 receptor was investigated and it was
found that it resulted rather from a homologous recombination event in the leukaemic
UPD-positive UPD-negative
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cells then from an allelic deletion. Interestingly, one patient with UPD in chr. 13 was
found without FLT3-ITD mutation, which was contrary to the possibility that FLT3-ITD
mutation could be responsible for homologous recombination repair. Based on these
results I wanted to find out if a FLT3-ITD mutation increased homologous
recombination in cells and if the DNA -damaging agents used in the treatment of
AML are limited by DNA repair pathways. For this, two vectors were used: pmHPRT-
DRGFP and pCbASce. The first vector (pmHPRT-DRGFP) carries a intact but
inactive GFP region, as well as a region with a mutated GFP with a restriction site –
SceI. The second vector (pCbASce) encodes the I-SceI homing endonuclease
(Fig.3.15).
Fig.3.15 Vectors system used for HR analysis.
The pmHPRT-DRGFP vector contains two GFP regions. One of them is inactivated by one
point mutation and I-SceI restriction size. The second GFP region is intact but inactive.
The pCbASce vector contains I-SceI endonuclease, which is able to generate double
strands breaks in the SceI restriction size in pmHPRT-DRGFP vector.
The pmHPRT-DRGFP vector is used for assaying double-strand break (DSB)-
mediated gene conversion in a mouse HPRT gene targeting complex. In this system,
the GR-GFP reporter is the first gene targeted to the mouse HPRT locus in a
quantifiable way. The cells successfully targeted with the reporter are transfected
with pCbASce carrying the I-SceI homing endonuclease. The upstream GFP repeat
(SceGFP) is nonfunctional owing to insertion of a recognition sequence for I-SceI;
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hence, I-SceI expression will generate a DSB in this repeat. The break can then be
repaired by several mechanisms including nonhomologous end joining (NHEJ),
single-strand annealing (SSA), and gene conversion-homologous recombination
(HR). HR results in repair of the DSB using the downstream internal fragment GFP
repeat (iGFP) as a template. As a result, SceGFP becomes a constitutively
expressed functional GFP+ gene and cells acquire green fluorescence easily
quantifiable by flow cytometry (Fig.3.16).
Fig.3.16 Different DSB repair products at the DRGFP locus.
HR, NHEJ and SSA are the possible DSB repair pathways but only HR results in GFP+ cells.
All three DSB repair pathways result in I-SceI site loss; the homologous repair pathways HR
and SSA additionally result in replacement of the I-SceI site with a BcgI restriction site.
When cells are supplied with an exogenous gene targeting construct, the construct
can integrate either into the homologous locus (targeted) or into random loci
(nontargeted). I used the nontargeted integration to investigate the repair
mechanisms in some human cell lines. After transfection, the cells were selected with
puromycin, whose resistance is carried by the vector. After the identification of cells
that have successfully integrated the DRGFP reporter, DSB-induced gene
conversion was quantified by assaying green fluorescence (GFP) after the
transfection of these cells with the expression vector for the I-SceI endonuclease
(pCbASce).
To determine whether the FLT3 mutation has a role in homologous recombination
(HR) in human cells the following cell lines were transfected with the pmHPRT-
DRGFP vector: MV4-11, Molm13, THP1 and K562, described in more detail in the
materials and methods section. MV4-11 expressed only  FLT3-ITD but not FLT3wt -
MV4-11 (FLT3-ITD), while Molm13 expressed FLT3-ITD as well as FLT3wt - Molm13
BcgI
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(FLT3-IDT/wt) (Table 3.4).  As a negative control THP1 (with expression of FLT3wt
only) and K562 (without any detectable expression of FLT3) were used (Table 3.4).
Table 3.4 Cell lines used in this project and the expression status of FLT3wt and FLT3-
ITD.
Cell lines Lineage FLT3-ITD status FLT3wt status
MV4-11 Myeloid Yes No
Molm13 Myeloid Yes Yes
K562 Myeloid No No
THP1 Myeloid No Yes
After the selection with puromycin for each cell line (the resistance level for each cell
line is described in the materials and methods section (2.14.4)) a single clone was
produced using FACSAria (Beckton Dickinson). I determined the single copies of the
pmHPRT-DRGFP by Real Time quantitative PCR. ß-Globulin gene was used as a
control. In Fig.3.17 the results from MV4-11 (FLT3-ITD) are shown. For example the
MV4-11_64 and MV4-11_71 contain more then one copy of the pmHPRT-DRGFP
vector. The remaining clones were with single copies of the vector. In the remaining
cell lines the same procedure was performed (data not shown).
Fig.3.17 Single clone analysis using Real Time quantitative PCR.
The single clones from MV4-11 (FLT3-ITD), Molm13 (FLT3-ITD/wt), K562 and THP1 were
selected and the clones with one copy of the pmHPRT-DRGFP cassette were detected using
Real Time quantitative PCR. ∆CT value is calculated as a difference between the
amplification of the GFP gene in the pmHPRT-DRGFP cassette and the ß-globulin gene. The
graph presents the results from MV4-11 (FLT3-ITD). Two of the 10 clones (MV4-11_64 and
MV4-11_71) have more then one copy of pmHPRT-DRGFP vector. The remaining clones
have single copies of the vector.
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Electroporation conditions were optimised before the transfection with the pCbASce
vector (Fig.3.18.A). The optimal electroporation efficiency was achieved using the
following electroporation conditions (Fig.3.18.B).
Cell line Voltage (V) Time constant (ms) Electroporation
efficiency (%)
MV4-11 300 7,5 45
Molm13 300 22,7 33,17
K562 300 6,6 87,85
THP1 250V 39,8 67
Fig.3.18 Electroporation efficiency and electroporation conditions in MV4-11 (FLT3-ITD),
Molm13 (FLT3-ITD/wt), K562 and THP1 cell lines.
2x107 cells washed with RPMI medium were mixed with 40µg pmHPRT-DRGFP vector and
after a 10 min ice-incubation were electroporated with BioRad (Gene Pulser II) under varying
conditions.
A. The highest electroporation efficiency achieved in each cell line.
B. The electroporation conditions used in each cell line.
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I chose one clone from each cell line with a single copy of pmHPRT-DRGFP vector
and transient transfection with pCbASce was done to generate a DSB. Five days
after transfection the GFP positive signal (caused by the repair of the DNA damage)
was measured by flow cytrometry (Fig.3.19).
To identify the homologous repair efficiency in the different cell lines, I related the %
of GFP positive cells to the electroporation efficiency. Surprisingly THP1 showed very
high HR efficiency compared to other cell lines. The HR capacity in K562 and MV4-11
(FLT3-ITD) was similar, but I couldn’t identify any GFP positive signal in Molm13
(FLT3-ITD/wt) this could be an indication of lack of HR-repair. The results are shown
in Fig.3.20.
THP1 HPRT - control THP1 HPRT – trasfected with
pCbASce vector
K562 HPRT - control K562 HPRT – trasfected with
pCbASce vector
MV4-11 HPRT - control MV4-11 HPRT – trasfected with
pCbASce vector
Fig.3.19 GFP positive signal
measured by flow cytometry.
From each cell line a single clone
containing one copy of pmHPRT-
DRGFP vector was transfected
with 40µg pCbASce vector using
electroporation. Five days after
transfection the GFP signal  was
measured.
In the left panels - as a control,
MV4-11, K562 and THP1
transfected only with pmHPRT-
DRGFP vector were used.
In the right panels - the GFP
signal as a result of HR occurs
after transfection with pCbASce
vector.
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Fig.3.20 Homologous recombination (HR) efficiency measured by flow cytometry.
From each cell line one clone with a single copy of pmHPRT-DRGFP vector was additionally
transfected with pCbASce to generate DSB. The result of the HR repair was a GFP positive
signal. The % of GFP positive cells was related to the electroporation efficiency from each
cell line. I couldn’t identify any GFP positive signal in Molm13 (FLT3-ITD/wt).
3.6.2 Analysis of the repair possibilities using Short Tandem Repeat (STR)
3.6.2.1 Homologous recombination
I developed a system to confirm the HR and analysed the repair possibility based on
STR analysis. I constructed one forward primer (Pr.1) at the end of the promoter
before the mutated GFP fragment and one reverse primer (Pr.2 – Fam labelled) at
the mutated position in the GFP fragment. The resulting fragment is 440bp long, is
fam labelled and shows the primary state of the pmHPRT-DRGFP vector before any
damage takes place. Also, as a second control I constructed the second pair of
primers before the intact GFP fragment (Pr.3) and in the middle of the intact GFP
(Pr.4 – Hex labelled). This fragment is 487bp long and it is Hex labelled. After HR the
new fragment with pr.1 and pr.4 could be detected. This new fragment is hex
labelled, 434 bp. long and it is a result of HR repair (Fig. 3.21.A/B and Fig.3.22).
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A. GFP casettes in pmHPRT-DRGFP vector
Fig.3.21 GFP system constructed to analyse the HR repair.
A. Primer state of the pmHPRT-DRGFP vector before any repair takes place. The mutated
GFP region with I SceI restriction size is not active. After the generation of DSB with
ISceI endonuclease in the mutated GFP region, the intact GFP region could be used as a
template in the HR repair process. After the amplification reaction with primers 1 and 2 a
fragment with 440 bp was produced. The fragment with primer 3 and 4 was 487 bp.
B. After HR the intact GFP fragment replaced the damaged GFP fragment. The resulting
fragment with primer 1 and 4 is a consequence of HR and is 434bp.
Fig.3.22 STR analyses of HR.
A. Before DSB occurred the primary fragment (with primers 1 and 2) was 440bp.
B. After the induction of DSB with SceI endonuclease HR took place and the new fragment
434bp (with primer 1 and 4) could be detected. HR was confirmed in THP1, K562 and
MV4-11.
A. B.
HR
B. After HR
Promotor Intact GFPBcgI BcgI Intact GFP
Promotor GFP with
mutation
I-SceI BcgI Intact GFP
HR
Pr.4 Hex
434bp 487bp
Pr.1 Pr.2 Fam Pr.3 Pr.4 Hex
440 bp 487 bp
Pr.4 HexPr.3Pr.1
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The area of the HR – pick was different in the different cell lines, but it corresponded
to the % of GFP cells measured by FACS (Fig.3.23). NPM1 was used as a single
copy control. The value was calculated as a difference between the area of the
NPM1 and the area of the HR pick. THP1 shows the highest value, while between
MV4-11 (FLT3-ITD) and K562 there was no significant difference.
Fig.3.23 Homologous recombination (HR) efficiency measured by STR.
From each cell line a single clone containing one copy of pmHPRT-DRGFP vector was
transfected with 40µg pCbASce vector using electroporation. Five days after transfection the
efficiency of HR in the different cell lines measured by STR analysis was calculated as a
value of the area of the HR picks and related to the NPM1 gene used as a control gene.
3.6.2.2 Nonhomologous end joining repair (NHEJ)
I used the same method based on STR analysis to find out the efficiency of NHER.
This process occurs in a relatively simple end-splicing mechanism, but led to the loss
of genetic information. I used two primers: the first one was primer 1 used above but
Bo TMR labelled and located before the mutated GFP fragment, and the second –
primer 5 was located after the cut place in the mutated GFP. The original fragment
before the induction of DSB was 563bp long. I expected that after NHEJ repair it
would be possible to identify fragments shorter than 563bp (Fig.3.24). After the
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transfection of MV4-11 (FLT3-ITD); Molm13 (FLT3-ITD/wt); K562 and THP1 with
pCbASce I proved the efficiency of NHER in all four cell lines, but I couldn’t find any
fragments shorter than 563bp. In Fig.3.25 the result of STR analysis in K562 is
present.
Fig.3.24 Primer system for detection of NHEJ repair.
Primer 1 Bo TMR and Primer 5 are constructed in the mutated GFP region in the pmHPRT-
DRGFP vector. The result is a fragment 563bp long. After the deletion fragments shorter
than 563bp should be identifiable.
Fig.3.25 Detection of NHEJ repair using STR analyses.
Primer 1 BoTMR and primer 5 were used to detect NHEJ repair in K562, MV4-11, Molm13 and
THP1 transfected with pmHPRT-DRGFP and pCbASce vectors. After the deletion fragments
shorter than 563bp should be identifiable. In all four cell lines I couldn’t found any NHEJ
repair. On the graph the results from K562 are presented.
Promotor GFP with
mutation
BcgI intact GFP
Pr.1 Bo TMR
After deletion the
fragment is shorter
than 563bp
I-SceI
Pr.5
Control K562 after the transfection
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3.6.2.3 Single-strand annealing
The other DSB repair pathway using sequence homology is single-strand annealing
(SSA). SSA is a highly efficient mechanism of DSB repair in mammalian cells
involving direct repeats. Because a large portion of the mammalian genome consists
of repeat sequences, SSA could potentially be an important alternative pathway of
homologous repair. In the pmHPRT-DRGFP system the two GFP fragments are very
close to each other so it makes this repair mechanism possible. The detection of
SSA repair should also be possible with the STR analysis. Between the mutated GFP
and the intact GFP the puromycin gene resistance is located. After SSA repair the
mutated GFP and the puromycin resistance gene are replaced by the intact GFP
gene. To detect this repair I used primer 1 Bo TMR and constructed an additional
reverse primer for the region located after the intact GFP gene. The original fragment
(before the repair took place) was 4440bp long and was not detectable with STR
analysis. After the SSA, the fragment detected with primers 1 Bo TMR and 6 should
be 850bp long and Bo TMR labelled (Fig.3.26). To make the detection of SSA repair
possible the cells are incubated without puromycin, because the resistance should be
lost after SSA repair. Unfortunately I couldn’t detect any SSA repair with this system
because of non-specific signals. I then used an indirect method to identify SSA in
these cell lines based on the primer 3 and primer 4 (Hex labelled). As shown above
(Fig.3.21) the resulting fragment obtained with these primers is 487bp. After SSA
repair this fragment can not be identified anymore. I compared the areas of the
resulting picks in all four cell lines after transfection with the pmHPRT-DRGFP vector
and compared them with the picks areas after transfection with pCbASce vector.
NPM1 was used as a control housekeeping gene. In MV4-11 (FLT3-ITD), Molm13
(FLT3-ITD/wt) and THP1 I couldn’t identify any SSA. In K562 I detected low level of
SSA but it was not possible to quantify this repair.
Results 80
Fig.3.26 Primer system for detection of SSA.
The fragment produced after the amplification with primer 1 Bo TMR and primer 6 (before the
induction of DSB with pCbASce) in pmHPRT-DRGFP vector is 4440bp long. After SSA the
new fragment with primer 1 Bo TMR and 6 should be 870 bp long.
With the pmHPRT-DRGFP system I could show that in proliferating cells the
homologous recombination repair predominates, as published by Hoeijmakers, 2001.
However it was not possible to clearly conclude whether there is a difference
between MV4-11 (FLT3-ITD) and MOLM13 (FLT3-ITD/wt)
 in the repair efficiencies.
Also I couldn’t find any differences in the repair efficiencies between cell lines with
FLT3 mutation (MV4-11) and without FLT3 mutation (K562 and THP1). To clarify this
uncertainty I chose another method based on the H2A.X phosphorylation which
allowed me to directly measure the repair efficiency in the primary cell lines.
3.6.3 Repair analyses using yH2Ax assay
In the primary treatment of AML patients often combination chemotherapy is used.
One of the currently using components is for example etoposide – DNA-damaging
agents. Etoposide is a topoisomerase II inhibitor, and it induces double strand breaks
SSA
4440bp
Promotor GFP with
mutation
I-SceI BcgI Intact GFP
Pr.1 Bo TMR Pr.6
Promotor Intact GFPBcgI
870bp.
Pr.1 Bo TMR Pr.6
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during DNA replication. DSBs induce a strong proapoptotic signal when damaged
DNA is left unrepaired, since cell survival relies on the efficiency of DNA repair. One
of the first enzymatic components to bind to the broken DNA ends is H2AX. H2AX is
rapidly phosphorylated (yH2AX) in the chromatin micro-environment surrounding a
DNA double-strand break (DSB). The measurement of the yH2AX provides
information about the DSB-repair efficiency in different cell systems. yH2A.X
phosphorylation assay was adopted to measure directly the repair efficiency in THP1,
K562, MV4-11 (FLT3-ITD) and Molm13 (FLT3-ITD/wt)). I incubated the cells for one
hour with etoposide to induce DSB and then, after three rinses in RPMI medium, the
cells were returned to the incubator for 2h to allow time for repair to take place. Then
cells were fixed and the yH2Ax phosphorylation was measured. The values from the
chemiluminescence intensity after the incubation with etoposide and after 2h repair
were compared and the difference defined the efficiency of repair calculated in %.
Following treatment of THP1, K562 and MV4-11 (FLT3-ITD) with etoposide, there was
a significant loss of yH2AX over 2 hours of repair, indicative of an active DSB repair
pathway in these samples. However, the incubation of Molm13 (FLT3-ITD/wt) with
etoposide demonstrated no loss of yH2AX after the same time period, indicative of a
lack of repair of DSBs (Fig.3.27).
Fig.3.27 Repair efficiency measured by yHA2x assay.
The cells were cultivated with etoposide for one hour. After the wash with RPMI medium they
were cultivated for an additional two hours in order for the repair to take place. The yH2Ax
chemiluminescence was measured after the incubation with etoposide and after the repair
time and the difference defined the efficiency of repair calculated in %.
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Despite the absence of FLT3 expression in K562 the repair efficiency is very high
and I couldn’t determine any difference between K562 and MV4-11 (FLT3-ITD). K562
contains the BCR-ABL1 fusion gene (K562 (BCR-ABL1)) and following previous
reports indicating the importance of the role of BCR-ABL fusion protein in the repair
process, so this possibility was also tested in this project. The results are described
below in the chapter 1. Additionally, to find out if the FLT3-ITD mutation has a direct
impact on repair, I used a specific inhibitor for the FLT3 tyrosine kinase receptor –
PKC412. The results are described below in chapter 2. Also the lower repair
capacity in Molm13 (FLT3-ITD/FLT3wt) compared to MV4-11 (FLT3-ITD) could be
explained by the effect of the heterozygosity state of FLT3 mutation in the cell repair
process. To confirm this possibility I used MV4-11 (FLT3-ITD) transfected with vector
containing the wt of FLT3 - MV4-11wt (provided by Dr. Sina Koch). The results are
present below in chapter 3.
Chapter 1. The effect of BCR-ABL on the DNA-repair
The K562 cell lines contains the BCR-ABL1 b3-a2 fusion gene, which has a
continuously active tyrosine kinase activity. The consequence is rapid proliferation of
leukocytes in CML patients. BCR-ABL1 fusion protein could be responsible for the
high repair efficiency published by Slupianek (Slupianek et al., 2001). To confirm this
I used Imatinib, which is a specific inhibitor of a number of tyrosine kinase enzymes
including abl, c-kit and PDGF-R (Platelet-derived growth factor). Before the repair
took place in the K562 (BCR/ABL), I first incubated the cells with Imatinib for four
hours and then with etoposide for 1h to induce DSB. The values of
chemiluminescence intensity after the incubation with etoposide and after a 2h repair
were compared, and the difference defined the efficiency of repair calculated in %.
As a control I used MV4-11 (FLT3-ITD) because it has no known inhibition effect from
Imatinib on other tyrosine kinases like FLT3. In Fig.3.28 it can clearly be seen that
the repair efficiency in K562 (BCR-ABL) incubated with Imatinib rapidly decreases
compared to K562 (BCR-ABL) without imatinib, while the repair capacity in MV4-11
(FLT3-ITD) with Imatinib doesn’t change compared to MV4-11 (FLT3-ITD) without
Imatinib incubation.
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Fig.3.28 Repair efficiency after the Incubation of K562 (BCR-ABL) and MV4-11(FLT3-ITD)
with Imatinib.
The cells were incubated for four hours with Imatinib (specific inhibitor of Abl kinase) followed
by incubation with etoposide and two hours repair time. The yH2Ax chemiluminescence was
measured after the incubation with etoposide and after the repair time and the difference
defined the efficiency of repair calculated in %.
Chapter 2. The effect of the FLT3-ITD mutation on the repair mechanism
To test if FLT3 mutation is responsible for a higher repair efficiency I used PKC412
(specific inhibitor of FLT3 kinase), which inhibits a number of class III tyrosine kinase
receptors, including FLT3. I incubated MV4-11 (FLT3-ITD) with PKC412 for 4h before
the incubation with etoposide. As a control I used K562 (BCR-ABL) because PKC412
has no inhibitory effect on BCR-ABL activity. In Fig.3.29 it is shown that PKC412
inhibits the repair efficiency in MV4-11 (FLT3-ITD), while there is no any effect in K562
(BCR-ABL) with and without PKC412 incubation.
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Fig.3.29 Repair efficiency after the incubation of K562(BCR-ABL) and MV4-11(FLT3-ITD)
with PKC412.
The cells were incubated for four hours with PKC412 (specific inhibitor of FLT3 kinase)
followed by incubation with etoposide and two hours repair time. The yH2Ax
chemiluminescence was measured after the incubation with etoposide and after the repair
time and the difference defined the efficiency of repair calculated in %.
As was described above, the HR efficiency measured by flow cytometry in MV4-11
(FLT3-ITD) transfected with the pmHPRT-DRGFP vector was about 3% (Fig.3.20). I
decided to confirm the inhibitory effect of PKC412 directly on HR as well. MV4-11
(FLT3-ITD) (transfected with pmHPRT-DRGFP and pCbASce vectors) was incubated
with PKC412 for four hours. The cells were washed 3 times and further incubated for
five days. As a control MV4-11 (FLT3-ITD) transfected with pmHPRT-DRGFP and
pCbASce vectors was used. The GFP signal (resulting from HR) was measured
using flow cytometry. I confirmed the HR of about 3% presented in Fig.3.20, but, as
expected, I couldn’t identify any GFP signal after PKC412 incubation (data not
shown).
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Chapter 3. Effect of the heterozygosity state of FLT3-ITD on the DNA repair
The next step in this project was to clarify if the missing of wt of FLT3 in MV4-11
(FLT3-ITD) increase the repair potential compared to Molm13 (FLT3-ITD/wt) (shown
above on Fig.3.27). For this reason MV4-11 (FLT3-ITD) transfected with vector
containing the wild type of FLT3 (MV4-11wt) was used for the measurement of the
yH2Ax phosphorylation and for the determination of the repair efficiency. The results
are shown in Fig.3.30. The repair efficiency decreased rapidly in MV4-11wt compared
to MV4-11 (FLT3-ITD). The level of the repair activity in MV4-11wt was comparable with
the level of repair in Molm13 (FLT3-ITD/wt). The very low level of repair in Molm13
measured with yH2Ax assays could be a possible explanation for the missing GFP
signal observed after the transfection with pmHPRT-DRGFP and pCbASce vectors
shown above.
Fig.3.30 Repair efficiency in MV4-11 (FLT3-ITD), MV4-11wt and Molm13 (FLT3-ITD/wt).
The cells were incubated for one hour with etoposide and after the wash procedure they
were incubated for additionally two hours. The yH2Ax chemiluminescence was measured
after the incubation with etoposide and after the repair time and the difference defined the
efficiency of repair calculated in %.
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3.7 Cell cycle analyses
Error-free, conservative HR repair involves strand invasion and requires a
homologous DNA template. It is generally believed to occur preferentially in the late
S, G2 and early M phases of the cell cycle, when the sister chromatid is available.
Next, I attempted to clarify the effect of etoposide on the cell lines using cell cycle
analysis. Additionally, the impact of the Imatinib and PKC412 followed by etoposide
incubation on the cell cycle distribution was analysed. The results from the incubation
of K562 (BCR/ABL), MV4-11 (FLT3-ITD), MV4-11wt (FLT3-ITD/wt) and Molm13 (FLT3-
ITD/wt) with etoposide (1h) and after a 2h repair, as well as after the incubation with
Imatinib and PKC412 (4h) followed by incubation with etoposide and a 2h repair are
shown below. I could identify significant changes in the cell cycles in all four cell lines
after the repair time. The 7h incubation of all four cell lines without inhibitors and
induction of DSB didn’t show any considerable changes and for this reason the
results are not shown. In the K562 (BCR/ABL) (Fig.3.31/Table1 and Fig.3.32.A.) the
fraction of the cells in the growth phases (S and G2/M phases) increased by 16.5%
after the repair time. The impact of a 4h PKC412 incubation was the immediate
16.5% increase of the cell fraction in the growth phase. This is a known effect of
PKC412 on leukaemic cells (Odgerel et al., 2007). This growth remained stable after
the repair time. The movement of the cell fraction in the growth phase may correlate
with the high repair efficiency measured after the incubation with etoposide as well as
after the incubation with PKC412/Etoposide by yH2AX assay (Fig.3.29). No changes
in the cell cycle in K562 (BCR/ABL) were observed after the incubation with Imatinib
(ABL inhibitor) and etoposide, which may correlate with low repair efficiency
measured by yH2AX assay (Fig.3.28).
I used the same procedure in measuring the cell cycle in MV4-11 (FLT3-ITD). After the
incubation with etoposide/repair time, the cells in the growth phase increased by
20.7% (Fig. 3.31/Table 2 and Fig. 3.32.B). Also a 12.8% increase of the cell fraction
in the growth phase was measured after the incubation with
Imatinib/Etoposide/repair. These results as well may correlate with the high repair
efficiency measured after the incubation with etoposide as well as after the
incubation with Imatinib/etoposide by yH2Ax assay (Fig.3.28). The impact of PKC412
on MV4-11 (FLT3-ITD) is similar to K562: immediately after four hours of incubation
with PKC412 (FLT3 inhibitor) the cell fraction increased by 20.5% in the growth
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phase. However, unlike K562 the cell fraction in the growth phase decreased rapidly
by 28.4% after the repair time, which is an indication of induction of apoptosis, as
judged by an increase in the size of the sub-G1 fraction (Fig.3.30/Table 2 and
Fig.3.31.B). Again, these results may correlate with very low repair potential after the
incubation with PKC412/etoposide measured by yH2Ax assay (Fig.3.29).
In contrast to K562 (BCR/ABL) and MV4-11 (FLT3-ITD), MV4-11wt (FLT3-ITD/wt) and
Molm13 (FLT3-ITD/wt) cells were arrested in the G1 phase after etoposide
incubation and 2h of repair, as well as after the incubation with Imatinib, PKC412 and
etoposide (Fig.3.31/Table 3/4 and Fig.3.32.C/D). Apoptosis was barely observed in
these cell lines up to 24 h after the repair time. These results may correlate with the
very low repair efficiency measured in MV4-11wt (FLT3-ITD/wt) and Molm13 (FLT3-
ITD/wt) using yH2Ax assay (Fig.3.30).
Fig.3.31 Cell cycle distribution of K562 (BCR/ABL), MV4-11 (FLT3-ITD), MV4-11wt (FLT3-
ITD/wt) and Molm13 (FLT3-ITD/wt).
Data are the means ± s.d. of n=3 independent experiments. Bold values indicate P<0.05.
The proportion of cells in each phase of the cell cycle was calculated with the ModFitLT 2.0
program.
K562 (BCR/ABL)
Control (%) Imatinib (%) pV PKC412 (%) pV
G0/G1
S+G2/M
33.61 (±2.08)
66.55 (±2.01)
34.64 (±0.72)
65.36 (±0.72)
0,6
0.5
16.98 (±1.36)
83.02 (±1.35)
0.001
0.001
1h etoposide
G0/G1
S+G2/M
46.94 (±4.08)
53.06 (±4.08)
36.12 (±2.91)
63.89 (±2.91)
0.11
0.11
16.18 (±2.08)
85.48 (±0.84)
0.004
0.01
2h Repair
G0/G1
S+G2/M
16.94 (±0.42)
83.06 (±0.42)
38.17 (±2,35)
61.82 (±2.35)
0,004
0.004
17.19 (±2,24)
82.42 (±1.88)
0.9
0.72
Table 1.
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MV4-11 (FLT3-ITD)
Control (%) Imatinib (%) pV PKC412 (%) pV
G0/G1
S+G2/M
54.81(±0.72)
45.19 (±0.72)
53.16 (±2.25)
46.84 (±2.25)
0.35
0.35
34.32(±1.15)
65.68 (±1.15)
0.002
0.002
1h etoposide
G0/G1
S+G2/M
48.67 (±0.5)
52.99 (±2.38)
46.08(±3.6)
53.91 (±3.61)
0.36
0.84
32.28 (±1.9)
67.72 (±1.89)
0.008
0.04
2h Repair
G0/G1
S+G2/M
34.11(±1.23)
65.89 (±1.23)
40.35(±2.96)
59.65 (±2.96)
0.15
0.15
62.73(±0.35)
37.27(±0.35)
0.001
0.001
MV4-11wt (FLT3-ITD/wt)
Control (%) Imatinib (%) pV PKC412 (%) pV
G0/G1
S+G2/M
58,58(±1,97)
41,42(±1,97)
56,00(±2,86)
44,00(±2,86)
0.06
0.06
52,5(±2,15)
47,48(±2,15)
0.16
0.16
1h etoposide
G0/G1
S+G2/M
63,17(±1.77)
36.83(±1.77)
62,37 (±3.35)
37.62 (±3.35)
0.78
0.78
63,83 (±2.9)
36.16(±2.9)
0.85
0.85
2h Repair
G0/G1
S+G2/M
94.52 (±1.84)
5.48 (±1.84)
89.77 (±3.96)
10.23 (±3.96)
0.11
0.11
90.45 (±1.56)
9.55 (±1.56)
0.08
0.08
Molm13 (FLT3-ITD/wt)
Control (%) Imatinib (%) pV PKC412 (%) pV
G0/G1
S+G2/M
63.79 (±2.92)
36.21 (±2.92)
65.41 (±2.74)
34.59 (±2.74)
0.46
0.46
46.56 (±0.79)
53.44 (±0.79)
0.02
0.02
1h etoposide
G0/G1
S+G2/M
64.96 (±1.86)
35.04 (±1.85)
63.92 (±1.97)
36.08 (±1.97)
0.08
0.08
46.42 (±0.53)
52.58 (±1.59)
0.005
0.02
2h Repair
G0/G1
S+G2/M
93.35 (±1.94)
6.65 (±1.94)
91.55 (±2.01)
8.45 (±2.01)
0.19
0.19
88.78 (±2.49)
11.22 (±2.49)
0.14
0.14
Table 2.
Table 4.
Table 3.
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Fig.3.32 Cell cycle changes in K562(BCR/ABL), MV4-11 (FLT3-ITD), MV4-11wt (FLT3-
ITD/wt) and Molm13 (FLT3-ITD/wt).
The cells were incubated with etoposide for one hour followed by further incubation for two
hours for repair to take place. Additionally the cells were incubated with Imatinib or PKC412
for four hours before etoposide-incubation. Cells were harvested at the indicated time points,
and stained with propidium iodide in preparation for cell cycle analysis. See Fig.3.31 for
quantification and statistical analysis.
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3.8 Expression of RAD51
The major enzymatic component of HHR in eukaryotic cells is RAD51, as cells
deficient in RAD51 accumulate DSBs after replication or at stalled replication forks. I
measured the expression of RAD51 in MV4-11 (FLT3-ITD), Molm13 (FLT3-ITD/wt)
K562 (BCR/ABL) and THP1 using Real Time quantitative PCR. The results are
presented in Fig.3.33. Despite the low repair efficiency in Molm13 measured by
yH2Ax assay (Fig.3.27) the RAD51 expression levels in all 4 cell lines were very
similar. I wanted to explain why despite the high expression of RAD51 in Molm13 the
repair efficiency is very low.
The major HR proteins such as RAD51, RAD52, RAD54 etc., are re-localised within
the nucleus in response to DNA damage to form distinct foci that can be visualised
by immunofluorescent microscopy (Haaf et al., 1995; Tan et al., 1999; Liu & Maizels,
2000; Essers et al., 2002; Tarsounas et al., 2004a). I next conducted an experiment
based on immunofluorescence to test if any differences in the localisation of the
RAD51 in the cells could be found. This could be a possible explanation of the
different repair levels. Molm13 contains FLT3-ITD mutation as well as wt of FLT3 so I
compared Molm13 (FLT3-ITD/wt) with MV4-11wt (FLT3-ITD/wt), MV4-11 (FLT3-ITD)
and K562 (BCR/ABL). I present here my preliminary experiments. The cells were
incubated with etoposide for 1h to create a DSB. After this the cells were rinsed in
RPMI medium and additionally incubated for 2h for repair to take place. RAD51
localisation was tested before the incubation with etoposide and after 2h repair. My
preliminary results indicated that the RAD51 in K562 (BCR/ABL) (with high repair
efficiency measured by yH2Ax assay) is mainly located in the cytoplasm before the
incubation with etoposide. However, during the repair time a larger fraction of RAD51
could be detected in the nucleus (Fig.3.34). Similarly, in MV4-11 (FLT3-ITD) (with high
repair efficiency measured by yH2Ax assay) RAD51 is mainly located in the
cytoplasm, but could also be seen in the nucleus, at higher levels than in K562
(BCR/ABL). After the induction of double strand breaks, a small increase in RAD51
levels in the nucleus could be observed (Fig.3.34). This data indicate that in both cell
lines the protein is imported into the nucleus during strand repair. In contrast, in
Molm13 and MV4-11wt (a cell line with low repair activity measured by yH2Ax assay)
RAD51 is also detectable in the cytoplasm and nucleus before the incubation with
etoposide, but after the repair time, the amount of RAD51 in the nucleus decreased
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rapidly. In Fig. 3.34 the results from MV4-11wt are presented. This is an indication that
the protein was exported to the cytoplasm, and is, as expected, not part of the repair
of DSB in the nucleus.
This data, although preliminary, indicate that in cell lines with different repair capacity
RAD51 is probably involved in different signalling pathways contributing to its
activation. Future experiments are necessary to prove if a direct association between
FLT3-ITD and RAD51 exists as well as if this connection is relevant to the RAD51
activation and to establish if these results are statistically significant.
Fig.3.33 Expression level of RAD51
measured by Real Time
quantitative PCR
The expression level in MV4-11;
Molm13; K562 and THP1 was
measured by Real Time quantitative
PCR using QuantiTect SYBR Green
PCR Kit. All 4 cell lines showed
simmilar level of RAD51 expression.
These results don´t correlate with the
different repair efficiency measured in these cell lines. GAPDH was used as a housekeeping
gene.
Fig.3.34; Page 92
K562 Control
K562 2h Repair
DNA RAD51 Merge
Expression of Rad51
19
20
21
22
23
24
25
1000000 copies MV4-11 THP1 K562 Molm13 100000 copies
C
t
Results 93
Fig.3.34 Confocal laser scanning microscopy of RAD51.
MV4-11, K562 and MV4-11wt cells were incubated with Etoposide followed by 2 hours
further incubation (repair time). Immunofluorescence double-labelling was performed to
identify the localisation of RAD51 in the cells before the etoposide incubation and after the
repair time. DNA was stained with DAPI.
The scale bar is equal to 25 µm.
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MV4-11wt Control
MV4-11wt 2h Repair
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4. Discussion
4.1 Screening of AML patients for LOH using GeneChip Mapping
10K Array
Cytogenetics is considered one of the most valuable prognostic determinants in
acute myeloid leukaemia (AML). The prognostic value of cytogenetic abnormalities
identified by metaphase cytogenetic (MC) is well established in many malignancies.
On the basis of response to induction treatment, relapse risk, and overall survival, the
patients with detectable chromosome abnormalities could be classified in three
prognostic groups – with favourable outcome, with poor prognosis and with
intermediate prognosis. However, in a significant proportion of AML patients who
show normal MC, this technique does not allow us further prognostic resolution. In all
likelihood, clonal defects are present in patients, but their detection is precluded by
low resolution of routine techniques. However some chromosomal aberrations were
reported, like point mutations in the FLT3 gene, inactivated mutations in
transcriptionfactor CEBPA and one of the most common mutations in the NPM1-
gene. Raghavan also reported on uni-parental disomy (UPD) in connection with AML
(Raghavan et al., 2005).
Generally, development of cancer in human is a consequence of activation of
protooncogenes and inactivation of tumorsupressor genes. Loss of genetic
information through micro or macro deletions is a very common mechanism
stimulating this process and transforming a normal cell into a cancer cell. The result
is loss of one of the two alleles (loss of heterozygosity (LOH)) with a consequence -
hemizygous genotype. The missing part can be duplicated from the remaining
homologue chromosome known as UPD. In fact, UPD is a form of LOH where one
allele is duplicated and a cell becomes a homologous genotype. When the duplicated
region contains a tumorsupressor gene, that remaining allele is inactivated by  point
mutation, and the result is a complete loss of function in this gene, causing the
development of cancer.
UPD was first described by Engel (Engel et al.,1980) who reported that it was likely
to occur through meiotic error (i.e. constitutional UPD) (Shuman et al., 2006 ; Smith
et al., 2007) and as a result of this germline event, all cells in the adult organism
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carry the same UPD region. However, this event can also occur in somatic cells (i.e.
acquired UPD) leading to development of cancer. Similar mechanisms of UPD have
been shown to be important in the inactivation of tumorsuppressor genes or
activation of oncogenes. One of these mechanisms occurs in the somatic cells during
mitosis. This UPD might arise from a chromosomal segregation error, in which one
allele is lost by anaphase lag and the remaining allele is then reduplicated, or it can
stem from a non-disjunction error (Strachan el al., 2004). A second mechanisms,
acquired segmental UPD can occur through mitotic recombination between pairs of
high-identity, low-copy repeats (LCRs) in the S/G2 phase of the cell cycle (Stephens
et al., 2006). Low-copy repeats (LCRs) can act as substrates for non-allelic
homologous recombination (NAHR) and can result in deletions, duplications,
translocations, or inversions of genomic segments located between the LCRs
(Stankiewicz and Lupski 2002; Shaw and Lupski 2004). Another mechanism might
be a double-strand break repair error, in which chromosomal breakage is followed by
reduplication through homologous recombination to compensate for the loss of a
segment.
Recently, UPD has been observed in different clonal haematologic disorders such as
polycythaemia vera (Kralovics et al., 2002),  childhood acute lymphoblastic
leukaemia (ALL) (Rogan  et al., 1995), hairy-cell leukaemia (HCL) (Forconi et al.,
2008), chronic lymphocytic lymphoma (CLL) (Lehmann et al., 2008), myelodysplastic
syndrome (MDS) (Wang et al. (2008), but also in solid tumors as breast cancer
(Murthy et al., 2002), uveal melanoma (White et al., 1998), Wilm’s tumors (Shearer et
al., 1999), retinoblastoma (Hagstrom et al., 1999), tumors associated with Beckwith-
Weidemann syndrome (Henry  at al., 1991), glioblastoma (Lo et al., 2008)  and
meningioma (Krupp et al. 2008).
This project concentrated on the detection, classification and partially on the
background of uni-parental disomy (UPD) in AML patients with normal karyotype. In
fact, UPD might be a common but previously unrecognised mechanism in cancer
development, because the karyotype appears ‘normal’ when examined by
conventional cytogenetic analysis. Raghavan was the first to use Affymetrix
technology to screen patients with AML for LOH changes, and to find that UPD
occurring as a result of mitotic recombination could be found in about 20% of the
AML patients with normal karyotype, but with unknown effect on AML development
(Raghavan et al., 2005; Gorletta et al., 2005).
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Within this work, in a group of 146 AML patients with normal karyotype and using
10K SNP arrays it was shown the utility of this technology platform to detect
chromosomal abnormalities such as UPD. I showed that this aberration was present
in 14% of the cases as either the sole abnormality or a concurrent defect (most
commonly with FLT3-ITD or NPM1 mutations). This abnormality was present in
various chromosomes starting from an undefined point and in almost all cases it also
affected the telomere. Very interesting was the detection of UPD in the blasts as well
as in the T-cells used as a disease free control in 6 patients. The possible
mechanism is unknown, but if the event causing UPD happens during meiosis, no
phenotypical anomalies occur, and this could be a possible explanation of UPD in the
healthy material. Unfortunately, no remission material was available to prove the
germline origin of the UPD in these 6 cases. Whether this event has an indirect
impact on the disease progression is also unknown, but my data point out the
necessity of analysing tumour-free material to confirm the somatic origin of the
alteration. Certainly, the patients with LOH in the T-cells were excluded from the
acquired UPD positive group.
In addition to the CN-neutral LOH, which cannot be detected by MC or fluorescence
in situ hybridization, SNP arrays can also identify duplications and deletions. After
screening 146 patients, I found three cases with losses of genetic information
previously classified as having a normal karyotype according to conventional
molecular diagnostics. Generally this technology improves the possibility of detecting
a cryptic lesion in patients with normal karyotypes. Also by using SNP arrays it is
possible to overcome several hurdles in cytogenetic analysis. First, the small DNA
requirement (250 ng per array) allows rapid and exact molecular analysis even when
very low cell numbers and small amounts of DNA are available. Second, the high
resolution allows a more refined analysis, resulting in more accurate breakpoint
determinations, detection of small deletions and amplifications, and identification of
small segments of unbalanced translocations. Third, the SNP arrays provide
information of chromosomal copy-number changes as well as single nucleotide
polymorphism (SNP) genotypes, and this combination allows the detection of copy-
neutral chromosomal aberrations such as UPD. However, SNP array technology can
detect most but not all types of abnormalities such as balanced chromosome
rearrangements - reciprocal translocations and inversions.
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In this project Affymetrix 10K arrays were used, although arrays with much higher
resolution are available from Affymetrix. The main reason for this is that this study
was designed to identify large regions of UPD as a result of mitotic recombination, for
which the 10K arrays are quite appropriate. However, higher-resolution arrays have
the potential to identify much smaller recombinations of only a few thousand base
pairs.
4.2 The impact of UPD on AML development
As was described above single gene mutations are an additional biological risk factor
in AML. A possible mechanism for relapse is one in which a heterozygous mutation is
followed by a mitotic recombination event or possibly by nondisjunction event (UPD)
leading to homozygosity and clonal evolution. UPD might yield tumors that are
homozygous for pre-existing mutations in genes, methylation of promoters of genes
and focal deletion of genes. Raghavan reported that one AML patient with UPD in
chr. 19q13.1 was homozygous for a CEBPA mutation (Raghavan et al., 2005).
Additionally he found two patients with AML and UPD in chr. 11p. One case was with
a homozygous methylated paternal H19 gene, whereas the other showed a
homozygous non-methylated maternal pattern. H19 gene, located at 11p15.5, is
normally methylated, and hence inactivated, in only the paternal allele. H19 is located
in domain 1 of the 11p15.5 imprinted gene cluster. UPD in this region causes
methylation or non-methylation of the H19 gene on both chromosomes which results
either in biallelic silencing or biallelic activation of H19 respectively. Homozygous
methylation was also identified in hepatoblastoma published by Suzuki (Suzuki. et
al., 2008). All these results show that the UPD event in AML patients could have an
important consequence in unmasking pre-existing mutations. Recently, some genes
in which mutations are directly associated with the development of AML have been
described. We sequenced some of the genes (RUNX1; WT1 and CEBPA) shown to
be responsible for AML development that were located in the UPD regions. In one
patient, with UPD in chr.19 we found an insertion in the CEBPA gene
(CCAAT/enhancer binding protein). In AML, heterozygous as well as homozygous
CEBPA mutations are well recognized (Lin LI et al., 2005). Although a biallelic
mutation is not required for AML, it is important for the disease development. This
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has been shown by Smith (Smith et al., 2004) in cases in which a germ line CEBPA
mutation is followed after a long latency by a second mutation leading to AML
development and normally, these biallelic mutations are associated with acquired
UPD of 19q (Wouters et al., 2007).
Another gene - RUNX1 (AML1), located in chr. 21, is the most frequent site of
translocations in acute leukaemia such as t(8;21)(q22;q22) associated with AML-M2
and t(12;21)(p13;q22) associated with paediatric ALL (Look, 1997). The fusion onco-
proteins resulting from these translocations, AML1-ETO and TEL-AML1, are well-
known fusion oncogenes. Moreover, point mutations in RUNX1 have been observed
in familial platelet disorder, a disease with predisposition to AML (Song et al., 1999;
Buijs et al., 2001; Michaud et al., 2002). In addition, mutations, some of which were
biallelic, have been observed in sporadic leukaemias (Osato et al., 1999;
Preudhomme et al., 2000). Previous reports classified RUNX1 as a tumorsuppressor
gene. In this study  two patients with UPD in chr.21 were found and point mutations
in RUNX1 gene were  detected in both of them. Moreover, I sequenced the WT1
(Wilms' tumor) gene, also classified as a tumorsuppressor gene (Kim et al., 1998), in
three patients with UPD in chr. 11, but a point mutation in only one of them was
found. I proposed that more than one potential mutational target may be located in
the UPD region, because relatively large regions of the genome are involved in this
event. Also located in the long arm of chr. 11, the MLL and CBL genes are known to
be responsible for leukaemia development. However, I found that these two genes
were located in the aberrant region in 3 of 4 patients with UPD in chr. 11q. Which
other genes from 11q could be additionally involved in disease progression is not
clear. Recent reports have shown that aberrations in chr. 11 are generally correlated
with intermediate to poor prognoses. My statistical analyses also show that the
patients with UPD in chr. 11 have the poorest outcome compared with the remaining
UPD positive cases and UPD negative patients. Moreover, I found that in patients
with UPD who achieved complete remission after induction chemotherapy, 60.0%
relapsed within the first 6 months. In contrast, the rate of relapse in patients without
UPD was only 38.2% (P=0.065). Generally the OS in the patients with UPD was
significantly lower compared with UPD negative cases.
Furthermore, I couldn’t find any connection between age, WBC-counts or sex and
UPD, but I found that the FAB M1 subtype was observed in 47.6% of the UPD
positive patients, compared to only 19.2% of the UPD negative patients (P=0.04).
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Again I found that UPD commonly correlated with FLT3-ITD, MLL-PTD or NPM1
mutations, but without significant differences.
The identification of new UPD regions in cancer might give us the opportunity to
discover new cancer-related genes that are mutated, deleted, methylated or
imprinted. This could have important implications for classifying cancers and might
provide insight into their pathogenesis, prognosis and treatment options.
4.3 Gene expression profiling of the UPD positive and UPD negative
cases
Gene expression profiling has been developed over the last years and has held
promises to improve diagnosis, risk classification, and outcome prediction in acute
leukaemias as well as in other human cancers. In fact, gene expression profiling in
AML is becoming well established and has already been proven to be valuable in
diagnosing different cytogenetic subtypes, discovering novel AML subclasses, and
predicting clinical outcome. Recently, gene expression profiling studies in AML
showed a remarkable level of concordance in findings that may ultimately lead to an
increasingly refined molecular taxonomy (Golub et al., 1999; Downing 2003). In the
present study, 14% of the AML patients with normal karyotype were found to have
UPD. The gene expression analyses could supply a valuable new approach to the
classification of this subgroup of AML. Therefore, I used the Affymetrix gene
expression system to compare some UPD positive patients with UPD negative
patients. I could demonstrate clearly, that the UPD-positive group and the UPD
negative group segregated in two different clusters based on different gene
expression profiles. Also some subgroups could be identified, for example UPD in
chr.11 together with UPD in chr.2. These results suggest that gene expression
profiling might become useful as a powerful tool to identify novel cluster groups and
potential targets for therapy. Furthermore, uniparental disomy may lead to alterations
in the expression levels of imprinted genes. In addition, variation in expression
between two alleles is common (Lo et al., 2003). Therefore, if it is maintained after
mitotic recombination, uniparental disomy could be associated with specific gene
expression patterns. Taken together, this could be used to identify new tumor
suppressor genes responsible for AML development. The detection and classification
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of new genes involved in the development of AML is very important for future
diagnostics and is significant in selecting the most appropiate therapies and
determining the clinical outcome not only in AML, but also in other malignancies.
Additionally, the identification of new lesions could allow for further stratification
within prognostic groups defined by the WHO.
4.4 The impact of FLT3-ITD on repair efficiency
In this study UPD was often diagnosed as a dual aberration with FLT3 or NPM1
mutations. FLT3 is a class III receptor tyrosine kinase (RTK) structurally related to
the receptors for platelet derived growth factor (PDGF), colony stimulating factor 1
(CSF1), and stem cell factor receptor (c-KIT). These RTK contain extracellular
domain composed of five immunoglobulin-like domains, one transmembrane region,
and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. FLT3
receptor is activated by binding of the fms-related tyrosine kinase 3 ligand (FL) to the
extracellular domain, which induces homodimer formation in the plasma membrane
leading to autophosphorylation of the receptor and subsequent signalling through
posphorylation of multiple cytoplasmatic proteins with important functions in the
survival, proliferation and differentiation of primitive hemopoietic progenitor cells.
FLT3 mutations consist of two major types: internal tandem duplication (ITD)
mutations of 3-400 bp (always in-frame) that map to the juxtamembrane region (25-
30% of AML patients); point mutations that most frequently involve aspartic acid 835
of the kinase domain (KD) but have also been found less frequently in several other
sites (5–12% of AML patients). The mutations mapping to the juxtamembrane region
(frequently insertions, but also point mutations) are sometimes referred to as length
mutations (LM) in the literature. Both types of mutations result in autophosphorylation
as well as phosphorylation of a number of proteins, either directly or indirectly.
Previous studies on diagnostic material have shown that FLT3-ITD is a marker of a
poor prognosis (Thiede et al., 2002; Whitman et al., 2001) and increases the risk of
relapse (Gale et al., 2005). Additionally, FLT3-ITD patients (without FLT3wt) have a
significantly shortened survival compared with FLT3wt and/or FLT3-ITD/wt patients.
More recently, reports have shown that the most important prognostic factor is not
the FLT3 mutations alone, but the allelic ratio of FLT-ITD/wt. Patients with a high
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mutant/wildtype ratio of the FLT3 receptor have a significantly shorter OS (Steudel et
al., 2003). The loss of the wt of FLT3 receptor in AML patients with FLT3-ITD
mutation is a consequence of deletions in chr.13. Cells with only one copy of the
mutated tyrosine kinase receptor (FLT3-ITD/-) have hemizygous genotypes -
FLT3ITD/-. Recently it was shown that in patients with normal karyotype the missing
part is duplicated by homologous recombination (Thiede et al., 2002). Numerous
signalling pathways are disturbed in the AML patients with FLT3-ITD mutation, but
generally they have a higher rate of treatment failure. An enhanced ability to survive
genotoxic assimilation might explain this clinical observation, leading us to focus on
the DNA repair process in FLT3-ITD positive patients. I identified 6 patients with
FLT3-ITD mutation and UPD in different chromosomes but not in chromosome 13.
Additionally, it was interesting to find one case with UPD in chromosome 13 but
without FLT3-ITD mutation. I proposed to investigate the impact of the FLT3-ITD
mutation on homologous recombination using pmHPRT-DRGFP/pCbASce vectors-
system and yHA2x assay. As expected, the homologous recombination measured
with pmHPRT-DRGFP/pCbASce vectors-system was the predominant repair
mechanism in haematopoetic cell lines, but I couldn’t find any difference between
FLT3-ITD positive and FLT3-ITD negative cells. Also the identification of SSA was
difficult with this vector system. The pmHPRT-DRGFP vector carries a gene
conferring resistance to puromycin. Puromycin is used only in cell biology as a
selective agent in cell culture systems, but it is toxic to prokaryotic and eukaryotic
cells. It is possible that in some aspects this toxicity has a negative effect on the
repair mechanism in the haematopoetic cell lines. To overcome this effect I next used
HA2x assay to measure the repair efficiency directly in the cells. With this assay and
using PKC412 (specific inhibitor of FLT3-ITD) I was able to confirm the impact of
FLT3-ITD on the repair process. The results after incubation with PKC412 of FLT3-
ITD cells was reduction of DNA repair; in contrast, no difference in the repair capacity
was observed in cells without FLT3 expression. Also Seedhouse demonstrated that
FLT3-ITD cells repair DSBs in DNA more efficiently than FLT3wt cells. Incubation
with PKC412 resulted in a reduction of DNA repair in FLT3-ITD cells but not in
FLT3wt cells. They also proposed that increased DNA repair in FLT3-ITD cells
contributes to the risk of disease relapse by allowing damaged leukaemia cells to
repair their genome, survive and mediate relapse (Seedhouse et al., 2006).
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Furthermore, in this project clear difference was shown in the repair efficiency
between the cells only with FLT3-ITD mutation and heterozygous (FLT3-ITD/wt)
cells; the FLT3-ITD cells rapidly enhanced the repair process while in heterozygous
(FLT3-ITD/wt) cells, the repair efficiency was very low. These results were confirmed
using cells with FLT3-ITD mutation (without FLT3wt expression) transfecting with a
vector containing FLT3wt. After the transfection a rapid decrease in the repair
capacity in the cells with FLT3-ITD/wt compared with the primary (FLT3-ITD) cells
was observed. Moreover, I showed that different mutations could be responsible for
the enhanced DNA repair, for example BCR-ABL translocation. Slupianek published
that the BCR-ABL1 fusion protein could be responsible for the high repair efficiency
(Slupianek et al., 2001). After incubation with imatinib (specific inhibitor of bcr-abl) the
repair efficiency rapidly decreased in the cells containing this aberration. No changes
in the repair capacity were found in the bcr-abl negative cells after incubation with
Imatinib. These results might also explain the high homologous repair efficiency
measured in the cell lines with FLT3-ITD mutation and cell lines without FLT3-ITD
mutation but with BCR-ABL translocation using pmHPRT-DRGFP/pCbASce vectors
system.
Error-free, conservative HR repair involves strand invasion and requires a
homologous DNA template. It is generally believed to occur preferentially in the late
S, G2 and early M phases of the cell cycle, when the sister chromatid is available.
Cell cycle analyses of the cell lines used in this work revealed a clear correlation
between the repair efficiency and cell cycle changes. The high repair efficiency is
related to the movement of the cell fraction in the growth phases (S and G2/M
phases). This conclusion was confirmed after the incubation with specific inhibitors
like imatinib and PKC412. PKC412 is a specific inhibitor for FLT3-ITD and induces
G2 arrest but not apoptosis in AML cell lines without aberrant FLT3 activation. In
contrast, PKC412- induces massive apoptosis without markedly affecting cell cycle
patterns in AML cell lines harbouring FLT3 mutations. After the incubation of FLT3-
ITD cells with PKC412 the repair potential decreased rapidly, correlating with the
arrest of the cell fraction in the G1 sub-phase. In contrast, after the incubation with
PKC412, high repair efficiency was observed in cells without FLT3 expression; this
was correlated with the increase of the cell fraction in the growth phases (S and
G2/M phases). Furthermore, after the incubation with imatinib, the repair efficiency in
cells containing BCR-ABL aberration rapidly decreased, an event associated with the
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arrest of the cell fraction in the G1 sub-phase. The cells without this aberration
maintained a high repair capacity aligned with the increase of the cell fraction in the
growth phases (S and G2/M phases). The very low repair efficiency of the
heterozygous (FLT3-ITD/wt) cells correlate with the arrest of the cell fraction in G1
sub-phase and induction of apoptosis.
All these results show clearly that the enhancement of the repair efficiency in cells
with FLT3-ITD mutation is correlated with the lag of the wt of the FLT3 receptor.
Probably in  patients with FLT3-ITD/wt genotype and UPD in other chromosomes the
repair capacity is not increased which was speculated at the start of these
experiments. Generally, the development of leukaemia is correlated with the co-
operation of a minimum of two mutations - “two hit” model (described in chapter
1.3.4). Recently, in mice models it was shown that FLT3-ITD mutation alone is not
enough for the development of AML disease phenotype. I suggest that the existence
of FLT3-ITD mutation could be responsible for the duplication of mutations in
tumorsupressor genes as a second event in the pathogenesis of AML. This
correlates with the detection of some mutations in genes in some of the UPD regions
described as important for AML development shown above (4.2).
4.5 Expression of RAD51
Aberrant signalling in FLT3-ITD cells occurs via a number of pathways, including
signal transducers and activator of transcription 5 (STAT5), mitogen-activated protein
(MAP) kinase and phosphatidylinositol 3 (PI3) kinase pathways (Hayakawa et al.,
2000; Mizuki et al,. 2000). STAT5 regulates the expression of a variety of proteins,
among them Bcl-x(L) and RAD51, by direct transcriptional activation. Bcl-x(L)
belongs to the family of Bcl-2 proteins and plays an essential role in resistance to
apoptotic cell death by preventing membrane hyperpolarization and mitochondrial
swelling in response to death stimuli (Heiden et al., 1997). Bcl-x(L) is overexpressed
in a high percentage of AML patients and confers a poor prognosis in these patients
(Schaich et al,. 2001).
RAD51 plays a central role in homologous recombinational (HR) repair of DNA
double-strand breaks (DSBs) (Daboussi et al., 2002). Elevated transcription of
RAD51 was shown to be dependent on STAT5 expression in BCR/ABL-transformed
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cells (Slupianek et al., 2001). The role of RAD51 in drug resistance appears to be
specific for drugs that induce DSBs, for example, etoposide as was published by
Lundin et al., who observed fewer DSBs and faster HR of DNA lesions in RAD51-
overexpressing cells after etoposide treatment compared to control cells (Lundin et
al., 2003). In addition, RAD51 plays a dual role in both HR of DSBs and telomere
protection from attrition and fusion (Tarsounas et al., 2004b).
Following previous reports indicating the importance of the role of RAD51 in
leukaemic cells, the expression level of this protein in cell lines without FLT3-ITD
mutation as well as with FLT3-ITD/- and FLT3-ITD/wt genotypes was investigated
using Real Time quantitative PCR. I couldn’t identify any correlation between the
expression level in the cells with and without FLT3-ITD as well as with FLT3-ITD/wt.
This result was in contrast to the very low repair efficiency measured in the FLT3-
ITD/wt cells. The major HR proteins such as RAD51, RAD52 and RAD54, are re-
localised within the nucleus in response to DNA damage to form distinct foci. To
investigate if this process was not disturbed in cells with low repair efficiency I
performed the visualisation of the location of RAD51 using imunofluorescence. My
previous results show that even though RAD51 could be found in the nucleus, it is
mainly present in the cytoplasm in all the cell lines I analysed. After the induction of
DSB, the nuclear amount of the RAD51 rapidly increased in cells with high repair
efficiency. In contrast, in the cells with very low repair efficiency the nuclear level of
RAD51 rapidly decreased. These data indicate that in cells with very high repair
potential this protein is imported into the nucleus during strand repair. In contrast, in
cells with low repair capacity the protein was exported to the cytoplasm, and is, as
expected, not part of the repair of DSB in the nucleus.
AML is a very heterogeneous disease and different signalling pathways are
dysregulated. Although it is possible that, in parallel to the STAT5 upregulation of
RAD51, other activating mutations and signalling pathways contribute to RAD51
activation. These data, although preliminary, indicate that in cell lines with wt FLT3,
different regulatory mechanisms are responsible for RAD51 expression. Future
experiments are necessary to clarify the association between FLT3-ITD or the wt of
FLT3 and RAD51, as well as the signalling background of the RAD51 regulation in
AML patients.
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5. Summary
Acute myeloid leukaemia represents a heterogeneous group of early stem cell
disorders. characterised by an uncontrolled expansion of malignant cells (“blasts”)
blocked at certain stages of myeloid differentiation. AML is the most common acute
leukaemia affecting adults with median age of 65 to 70 years. This disease is
genetically very heterogeneous and is associated with diverse cytogenetic
abnormalities such as chromosomal deletions, translocations and duplications. The
outcome for patients with AML depends greatly on the age of the patient and
leukaemic cell karyotype. For this reason the diagnosis of the karyotype is one of the
most important factors to determine patient outcome. The development of new
methods of diagnosis and the classification of different genetic aberrations present in
leukaemia is very important for the treatment of this disease.
This study focused on the detection, classification and partially on the background of
uniparental disomy (UPD) in adult patients with AML. The following results were
obtained:
1. Using Affymetrix technology 14% UPD was identified in one group of 146 patients
with normal karyotype. In 6 patients this aberration was found in the blast as well
as in the T-cells, with unknown impact. Additionally deletions in three patients
previously classified with normal karyotype according to conventional molecular
diagnostics were detected. Generally this technology improves thus the possibility
of detecting a cryptic lesion in patients with normal karyotypes.
2. The relationship between UPD and AML was confirmed with the detection of
specific gene aberrations in some UPD regions. Furthermore, the obtained data
indicate that patients with UPD have a higher rate of treatment failure and this
might be used as a prognostic marker in the future.
3. It was demonstrated that the UPD positive group and the UPD negative group
segregate in two different clusters based on different gene expression profiles.
These preliminary results suggest that gene expression profiling might become
useful as a powerful tool to identify novel cluster groups and potential targets for
therapy.
4. Furthermore, the available results demonstrated that FLT3-ITD mutation
increased the DSB repair by homologous recombination rapidly. It was shown
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also that PKC412 inhibits the DSB repair in FLT3-ITD positive cells. In contrast, in
cells without FLT3 expression after the incubation with PKC412, no changes in
the repair efficiency were observed. Also differences were found in the repair
efficiencies between FLT3-ITD cells and FLT3-ITD/wt cells. The heterozygous
cells clearly showed low repair efficiency compared to the FLT3-ITD cells. This
was confirmed by transfection of homozygous FLT3-ITD cells with FLT3wt vector.
After the transfection the repair efficiency in FLT3-ITD/wt cells decreased rapidly
compared to the primary FLT3-ITD cells. Additionally, It was demonstrated that
also another mutation, BCR-ABL, increased the HR repair. After the inhibition of
the BCR-ABL activity using Imatinib (bcr-abl inhibitor) the repair efficiency
decreased rapidly.
5. The preliminary results suggest that not only the expression of RAD51, but mainly
its localisation, is important for its HR repair capacity. Moreover, RAD51
supposedly is involved in different signalling pathways in FLT3-ITD cells and
FLT3-ITD/wt cells as well as in the FLT3wt cells.
On the basis of these data and data from literature I can conclude that UPD is a
common aberration in AML patients with normal karyotype. I suggest that this
aberration constitute a „second hit“ event in leukaemia development and different
tumor supressor genes could be involved in this process. The event of HR is
associated with the high DSB repair capacity resulting in the impact of different
mutations such as FLT3-ITD or BCR-ABL. Moreover, I found that the wt of FLT3 is
able to eliminate the high repair capacity of the FLT3-ITD mutation. This correlates
with of the finding that the patients with DLT3-ITD/wt have better prognosis
compared to the patients with very high FLT3-ITD ratio. The high DSB repair capacity
enhances the ability to survive genotoxic assimilation by chemotherapy drugs, and it
may at the same time contribute to the high incidence of relapse. These results imply
that downregulation of RAD51 (for example by FLT3 inhibition) would be valuable
before DNA damage occurs through the genotoxic agent in order to reduce the
relapse risk of AML.
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